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The rapid influx of new treatment options for metastatic renal cell carcinoma (mRCC) 
pose unique challenges in clinical practice, as therapies are orally administered in the home, 
raising concerns in medication taking behavior. Consequently, there is a growing need to 
understand medication adherence and persistence in patients diagnosed with mRCC. Healthcare 
claims data can be used to fill this evidence gap. However, high mortality in the metastatic 
setting have important implications for study validity when using these data. To address 
methodological challenges, the goals of this dissertation were (1) develop and validate an 
algorithm to identify patients with incident mRCC and (2) compare approaches for measuring 
adherence and persistence in patients with incident mRCC who initiated a first line oral targeted 
therapy (TT).  
   Adults aged ≥ 66 were identified in the Surveillance, Epidemiology, and End Results 
(SEER)-Medicare linked database (2007-2015).  
   For Aim 1, reference standard mRCC cases were identified using registry data; a 
random 5% sample without mRCC served as the source population. Cohorts, advancing over 
time, were created, allowing cases to contribute information prior to cancer diagnosis. Claims-
based algorithms were evaluated, showing high specificity (>99.98%), high variation in 
sensitivity (28%-79%), and generally lower positive predicted values (14%-42%). Future   
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validation studies are needed to explore more complex algorithms that can achieve a higher PPV. 
Until then, researchers should consider the appropriateness of using code-based algorithms for 
mRCC cohort identification.   
 For Aim 2, we identified mRCC patients who initiated oral TTs within four months of 
diagnosis. We estimated adherence to TTs using the proportion of days covered ≥80%. After 
excluding patients who died, 6-month adherence was higher (60%) compared to assigning zero 
days covered after death (47%). Risk of non-persistence, obtained using Kaplan Meier methods, 
was higher after censoring death, 0.91 (95% confidence interval (CI): 0.88, 0.94) compared to 
the risk obtained using cumulative incidence functions and treating death as a competing risk, 
0.75 (95% CI: 0.71, 0.79). Different approaches to handling death resulted in different estimates 
of adherence and persistence. This may introduce bias in the metastatic setting where short-term 
mortality is common. Therefore, future studies should use appropriate methods to account for 
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CHAPTER 1: SPECIFIC AIMS 
Each year, approximately 18,000 Americans are diagnosed with metastatic renal cell 
carcinoma (mRCC), a devastating disease with five-year overall survival of less than 8%.3,4 
Targeted therapies (TTs) have dramatically changed the clinical landscape for the treatment of 
mRCC, with thirteen drugs receiving approval since 2005. The rapid influx of new treatment 
options pose unique challenges in clinical practice, as: (1) patients who initiate first-line TTs 
often switch to a second-line agent due to treatment failure, drug resistance, or toxicity5, and (2) 
most therapies are orally administered in the home, raising concerns about medication adherence 
and persistence. Yet, little is known about the real world adherence and persistence to TTs for 
mRCC. 
Healthcare claims data represent a potentially powerful resource to fill this evidence gap. 
These data capture detailed, longitudinal information on diagnoses, procedures, medications, and 
healthcare visits for well-defined patient populations in routine clinical practice. However, there 
is no consensus about the gold standard for measuring adherence or persistence. Claims-based 
studies of medication adherence and non-persistence rely on the date of prescription fill and 
days’ supply. However, this approach assumes that if a medication is dispensed, it has been taken 
as prescribed. Application of these same measures becomes challenging in the metastatic setting 
where death is a major competing risk for therapy continuation. Despite several published studies 
describing common methods for measuring treatment adherence and persistenc6, there is no 
documented guidance in a high-mortality population such as in the mRCC setting.  
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Moreover, because claims data are generated for billing and not research purposes, they 
often lack clinical detail that can hinder study validity. To minimize the potential for 
misclassification by using diagnoses codes alone in claims data, researchers often develop 
algorithms to identify the health outcomes of interest by combining diagnosis codes, prescription 
fills, and/or specific procedures to improve the accuracy of outcome definitions. To date, no 
study has developed a claims-based algorithm to identify incident mRCC.  
The overarching goal of this dissertation is to address critical challenges in designing and 
analyzing adherence and persistence studies in large healthcare claims databases in the metastatic 
setting. To achieve this objective, we sought the following aims: 
Specific Aim 1: Develop, validate, and compare algorithms to identify individuals with 
mRCC in claims databases. 
Aim 1 sought to construct the following algorithms to identify incident mRCC cases in SEER-
Medicare linked database for the years 2007 through 2015: 
1. Algorithm 1. ICD-9 diagnosis codes for metastatic cancer alone.  
2. Algorithm 2. ICD-9, HCPCS, and CPT codes reflecting the clinical pathway for 
diagnosing and treating mRCC  
Algorithms were validated against the reference standard defined as incident stage IV RCC cases 
identified in SEER-Medicare linked database (age 65 and older). Sensitivity, specificity, and 
positive predicted values were obtained for each algorithm and compared to identify an optimal 
algorithm to apply to claims databases.  
Rationale: To date, no study has validated algorithms to identfy patients with incident mRCC 
despite increasing claims-based research to understand treatment utilization, medication taking 
behavior, and health outcomes in patients diagnosed with mRCC. 
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Specific Aim 2: Compare approaches for measuring medication-taking behavior in high-
mortality populations, such as patients diagnosed with mRCC. 
Aim 2 explores various approaches for quantifying medication adherence and persistence when 
death is a major competing risk.  Patients newly diagnosed with mRCC who initiated a first-line 
oral TT were identified in the SEER-Medicare linked database for the years 2007-2015.  
Rationale: Current existing adherence and persistence studies focus on non-metastatic cancers, 
explicitly excluding patients who have metastatic disease or die. Despite, high risk of mortality 
of a shorter periods of time from diagnosis, longer-term survival for mRCC patients have been 
improving with the advent of new anti-cancer treatments. Thus, medication adherence and 
persistence is an emerging issue. Yet, no guidance for navigating death as a competing risk in 




CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
A. Pathophysiology and diagnosis of metastatic renal cell carcinoma 
Kidney cancer typically develops in the lining of the kidney tubules.4 The most common 
type of kidney cancer is renal-cell carcinoma (RCC) which originates in the renal cortex, and 
constitutes up to 85% of all kidney neoplasms with various subtypes.7 Major subtypes of RCC 
with ≥5% incidence are clear cell RCC, papillary RCC and chromophobe RCC.8-10 The 
remaining 10% of kidney cancers include transitional cell carcinomas, Wilms tumors, and renal 
sarcomas.4 The most common sites of metastasis include the lungs, lymph nodes, bone, liver, and 
brain. 
Patients with RCC can present with a range of symptoms and/or laboratory abnormalities 
including flank pain, hematuria, and a palpable abdominal renal mass.11 These symptoms are 
typically indicative of locally advanced disease. Patients with mRCC typically present with bone 
pain, adenopathy, and pulmonary symptoms attributable to lung parenchyma or mediastinal 
metastases.12 Patients with symptoms suggestive of RCC must undergo image evaluation for the 
presence of a renal mass. Through radiographic imaging, often a computerized tomography (CT) 
scan, RCC will typically present with a suspicious mass involving the kidney. With the 
increasing use of radiographic scans of the abdomen, a large proportion of RCC diagnoses are 
incidental.11 Further imaging tests may be conducted as part of diagnostic work-up. Partial or 
radical nephrectomy followed by active surveillance is the often recommended treatment for 
patients with localized RCC. Figure 1 describes diagnostic work up and treatment
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recommendations by stage for RCC diagnosis according to the National Comprehensive Cancer 
Network treatment guidelines.11 
B. Epidemiology of renal cell carcinoma 
Kidney cancer is the 7th most common cancer worldwide in men, and the 10th most 
common cancer worldwide in women accounting for 2–3% of all adult malignancies.4,13 The 
lifetime risk for developing kidney cancer is approximately 1 in 63 (1.6%).1 In 2018, over 
400,000 new cases of RCC were diagnosed, which represented the 5% and 3% of all cancers in 
men and women respectively.13 Incidence rates were highest in Asia, Europe and the United 
States (US) with 149,000, 136,000 and 60,000 new cases, respectively. After decades of 
increasing RCC incidence worldwide, incidence and mortality rates have levelled.13 However, 
the incidence of RCC is projected to increase over the next decade with the growing aging 
population and increasing prevalence of risk factors.7,14  
RCC most commonly occurs in older adults. There are very few cases of RCC in early 
adulthood, but beginning at the age of 40, the rates begin to rise steeply with the average age of 
diagnosis of 64 years.3,4 RCC is also twice as common in men as in women. A higher 
predisposition in males may be due to lifestyle factors such as cigarette smoking which has 
historically been higher in males and differing occupational exposures to industrial 
carcinogens.15,16 Other risk factors for RCC include obesity, and hypertension with a small 







Figure 1. 2017 National Comprehensive Cancer Network guideline recommendations for diagnostic work up and treatment decisions 
for kidney cancer diagnosis11
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Early hematogenous dissemination is a hallmark of RCC. Approximately 30% of all 
patients with RCC will present with synchronous metastasis at the time of diagnosis, while 
another 20%-30% of organ-confined cancers relapse and develop metastasis.11,20-22 Of those with 
localized disease treated with nephrectomy with curative intent, 42% will have relapses in distant 
sites in less than 12 months. Patients diagnosed with mRCC have a dismal prognosis with a five-
year overall survival of only 12% for mRCC patients.4,23 Approximately 40% of RCC patients 
die of metastases.24 Appropriate management of mRCC is becoming an increasing concern 
especially as rates of RCC incidence and mortality are projected to increase in the next decade 
with the growing aging population.14,25 
 
 FDA=Food and Drug Administration; mRCC=metastatic renal cell carcinoma 
 
C. First- and second-line therapies in mRCC 
Marked advances have been made for the treatment of mRCC resulting in improved 
survival rates over the past decade.26  New therapies, including vascular endothelial growth 
factor (VEGF)  tyrosine kinase inhibitors (TKIs), mechanistic target of rapamycin (mTOR) 
inhibitors, and PD-1/PDL-1 inhibitors have dramatically changed the clinical landscape for 
Figure 2. FDA approved therapies for mRCC over time1 
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mRCC, with 13 new drugs and drug combinations receiving Food and Drug Administration 
(FDA) approval since 2005 (Figure 2).1,11  
 
 
C.1. Cytokine-based therapies.  
Historically, before the introduction of TTs, cytokine‐based therapy with interferon‐
α (IFN) and/or interleukin‐2 (IL‐2) were considered standard first‐line treatment for patients with 
metastatic RCC (mRCC). Prior to approval for combination use with bevacizumab in 2009, IFN 
alone was approved in 2002 to treat mRCC. High-dose IL-2 was also approved for mRCC 
treatment in 2002. Both are administered intravaneously.27 However, the response rates were low 
at approximately 15%, survival was limited, and treatment‐related toxicities restricted their 





usage.28 In addition, previous studies of other therapies for cytokine‐refractory patients with 
RCC were unable to show benefit.29 
C.2. Targeted therapies.  
In the mid-2000s, through the discovery of the Von Hippel-Lindau (VHL) gene and its 
role in RCC pathogenesis, two cellular signaling pathways, VEGF and mTOR pathways, were 
identified as relevant targets for molecular therapy in RCC (Figure 3).30 Compared to 
chemotherapies, targeted therapies selectively seek out cancer cells based on molecular 
characteristics involved in cellular growth and proliferation as opposed to acting on all rapidly 
dividing normal and cancerous cells.31 They also more often block tumor proliferation compared 
to killing tumor cells.  
C.2.1. VEGF-TKI pathway in RCC 
Phenotypically, RCC is a highly vascular tumor with increased levels of VEGF, thus 
cellular growth could be stimulated by factors produced through the HIF-1 pathway.32 The VHL 
gene is a tumor suppressor gene that encodes the VHL protein, and plays a role in tissue-specific 
responses to oxygen concentration and delivery. More specifically, the VHL protein is a 
component of an E3 ubiquitin ligase complex which regulates hypoxia‐inducible factor‐1α 
(HIF), a transcription factor that controls the response of cells to low oxygen, including the 
expression of VEGF. Under normal oxygen levels and normal VHL gene function, VHL protein 
targets HIF for degradation. If the VHL gene is mutated or inactivated, HIF will not be degraded 
leading to an accumulation of HIF. Activated HIF translocate into the nucleus and leads to the 
upregulation or activation of several hypoxia-inducible genes, including VEGF and platelet-
derived growth factor (PDGF). These ligands bind to their receptors present on the surface of 
endothelial cells, subsequently leading to cell migration, tumor proliferation, and neovasculature 
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formation.30 Several therapies have been developed to inhibit the VEGF pathway in mRCC 
tumors including sorafenib, sunitinib, bevacizumab, pazopanib, axitinib, and cabozantinib. A 
summary of approved VEGF inhibitors for mRCC treatment can be found at the end of this 
section in Table 1.  
Sorafenib. The first TT to treat patients with mRCC was approved by the US FDA in 
2005.33 It is an orally administered drug taken once daily. Sorafenib is a VEGF TKI, an active 
multikinase inhibitor that inhibits cell surface tyrosine kinase receptors (e.g. VEGF and PDGFR 
receptor-β) and downstream intracellular serine/threonine kinases.34 Compared to IFN, clinical 
studies showed patients on sorafenib generally had fewer kidney cancer-related symptoms and 
concerns, better overall quality of life, and greater global treatment satisfaction, yet no difference 
in progression free survival (PFS) and overall survival (OS).34 
Sunitinib. Approved for mRCC treatment in 2006, sunitinib is an orally administered 
VEGF TKI taken once daily in 4 week cycles with 2 weeks of no therapy in between cycles.35 
Sunitinib is a multitargeted TKI of the VEGFR-1, VEGFR-2, PDGFRα, and PDGFRβ. Clinical 
studies have demonstrated drug superiority in overall health outcomes with sunitinib over IFN, 
with significantly longer PFS and OS.36 In an expanded access trial of patients ineligible for 
registration‐directed trials, clinical benefit was observed in both treatment‐naïve and previously 
treated patients, both older and younger patients, and patients traditionally with a poor prognosis, 
including patients with brain metastases.37,38 Based on clinical evidence, sunitinib is considered 
the current standard of for mRCC.  
Pazopanib. Pazopanib is another orally administered VEGF inhibitor that was approved 
in 2010.39 It inhibits VEGF receptor-1, -2 and -3, PDGFR-α and -β, and the stem cell factor 
receptor c-Kit, resulting in inhibition of tumour angiogenesis, cell growth and survival.40  
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Studies have shown that it may be better tolerated in elderly patients and in those with multiple 
comorbidities, which may impact patients’ healthcare resource utilization and healthcare 
costs.41 
Bevacizumab plus interferon-α. Bevacizumab was approved in 2009 for the treatment 
of mRCC in combination with IFN.42  Bevacizumab is a VEGF inhibitor administered 
intravenously once every two weeks.  Bevacizumab is a humanized monoclonal antibody 
directed against the VEGF by binding to VEGF and inhibiting VEGF receptor binding, thereby 
preventing the growth and maintenance of tumor blood vessels. Clinical studies of this 
combination compared to placebo plus IFN showed longer PFS.43  
Cabozantinib. Cabozantinib is a VEGF TKI inhibitor that received FDA approval for 
second-line treatment in mRCC patients in 2016 and is administered orally once daily.44  
Cabozantinib targets and inhibits both the VEGF pathways, and downstream targets implicated 
in tumor resistance.45 Studies have shown a longer PFS and increased OS with cabozantinib 
when compared with everolimus which makes cabozantinib a preferred choice in the second-line 
setting for advanced RCC after 2016.  
C.2.2. mTOR pathway in RCC.  
Activation of the mTOR pathway can also lead to HIF accumulation through cellular 
stimuli and the phosphoinositide 3-kinase pathway. mTOR is a serine–threonine kinase that 
contributes to the regulation of cell growth, proliferation, survival, and metabolism through 
phosphorylation and activation of the p70S6 kinase which leads to enhanced translation of 
certain proteins, including HIF. RCC tends to be a highly vascular tumor with high expression of 
VEGF, VEGF receptor, PDGF receptor, and basic fibroblast growth factor.46  Two TTs have 
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been developed to inhibit the mTOR pathway in mRCC tumors: everolimus and temsirolimus. A 
summary of mTOR inhibitors approved for mRCC treatment can be found in Table 1.  
Temsirolimus. Approved in 2007, temsirolimus is a selective inhibitor of mTOR and 
binds with the FK506-binding protein-12 to form a complex that inhibits the intracellular 
serine/threonine kinase activity of mTOR, preventing the translation of key proteins regulating 
the cell cycle so that cell is blocked in the G1 phase and angiogenesis is inhibited.47 
Temsirolimus is administered intravenously over a 30-60 minute period once per week.48 A 
phase III trial patients treated with temsirolimus alone had a statistically longer OS than patients 
in the IFN-α monotherapy group. Overall survival benefit was most notably demonstrated in 
poor-risk advanced RCC.47   
Everolimus. Everolimus is an mTOR inhibitor approved in 2009 for second- and third-
line treatment of mRCC and is administered orally once daily.49 It binds the intracellular receptor 
protein FKBP12 with to form the FKBP12/everolimus complex, which specifically inhibits 
mTORC1, ultimately interfering with mRNA translation of genes involved in cell cycle 
regulation and cellular response to hypoxia.50 According to the results of a Phase III pivotal trial 
that demonstrated a benefit in median progression-free survival of ~2 months compared to 
placebo after failure of previous lines of therapy.50  
C.2.3. TKI + mTOR combinations. 
Everolimus + Lenvatinib. In 2016, the FDA approved the combination treatment of 
everolimus (mTOR) and lenvatinib, a (VEGF-TKI) for second line treatment in patients 
diagnosed with mRCC. Lenvatinib is another multikinase inhibitor against the VEGF kinases. 





More recently, several immunotherapies have been approved for the treatment of mRCC. 
Cancer immunotherapy rests on the premise that tumors can be recognized as foreign rather than 
as self and can be effectively attacked by an activated immune system.52 Immune cells can 
recognize neoplastic cells and mount antitumor responses through the recognition of 
neoantigens, which are cell surface proteins expressed on neoplastic cells. However, tumor cells 
avoid an immune response by exploiting checkpoints that control the regulatory immune 
response, including display of antigens and control of co-stimulatory pathway that affect the 
proliferation of cells involved in immunity. A summary of immunotherapies approved for mRCC 
can be found in Table 1.  
Nivolumab.  Nivolumab was approved in 2015 for second line treatment of mRCC. It is 
a programmed cell death protein 1 (PD1) humanized monoclonal IgG4 immune checkpoint 
monoclonal antibody (mAB) enabling T-lymphocytes to target cancer at the cellular level and 
prohibits immune cell deactivation.53  Nivolumab is intravenously administered over a 60-min 
infusion every 2 weeks until disease progression.54 
Nivolumab + Ipilimumab. Ipilimumab was approved in 2011 for late-stage melanoma.55 
The combination of Nivolumab + Ipilimumab was approved for first-line treatment of 
intermediate and poor-risk advanced RCC in 2018. Ipilimumab is a fully human IgG-1 antibody 
that binds to the CTLA-4 molecule CTLA-4, a protein receptor that downregulates the immune 
system. Blocking signaling through the CTLA-4 molecule results in unrestrained activation of T 
cells, which can translate into meaningful clinical response. Clinical studies have shown higher 
OS compared to sunitinib.  
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Pembrolizumab + Axitinib. In 2019, the combination of pembrolizumab and axitinib 
were approved for the first-line treatment of patients with advanced RCC. Pembrolizumab is an 
immune checkpoint inhibitor, selective, fully humanized immunoglobulin G4-κ monoclonal 
antibody against PD-1 and is combined with axitinib, a TKI. Pembrolizumab is received in 200 
mg doses intravenously every 3 weeks in combination with axitinib 5 mg orally twice daily. 56 
Avelumab + Axitinib. In 2019, the FDA also approved the drug combination avelumab plus 
axitinib for first-line treatment of patients with advanced RCC.57 Avelumab is also an 
immunotherapy that also targets the protein PD-L1 and is administered as an intravenous 
infusion (800 mg) every 2 weeks in combination with oral axitinib (5 mg) twice daily. 





D. Evidence to support clinical decisions for mRCC treatment  
Increasing options for first- and subsequent lines of treatment have led to great challenges 
in treatment decisions for mRCC patients as optimal therapy in the first-line setting continues to 
evolve. Moreover, complete response to treatment with first-line therapy is rare and disease 
progression remains a clinical challenge. Patients who initiate first-line TT often switch to a 





class Drug type 
Mode of 
administration Dosing Schedule  
Interferon-α58 1992 IFN Immunotherapy 
Intravaneous 
injection Once daily 5x a week 
High-dose 
interleukin-227 1992 cytokine Immunotherapy 
Intravaneous 
injection 2x a week  
Sorafenib33 2005 VEGF 
Targeted 
therapy Oral twice daily 
Sunitinib35 2006 VEGF 
Targeted 
therapy Oral 
Cycles of once daily for 4 
weeks followed by 2 weeks 
off  





Infused over a 30¬-60 
minute period once per 
week  
Everolimus49 2008 mTOR 
Targeted 
therapy Oral  Once daily 
Bevacizumab + 




injection Every 2 weeks 
Pazopanib39 2010 VEGF 
Targeted 
therapy Oral Once daily 
Axitinib59 2012 VEGF 
Targeted 
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second-line agent due to treatment failure, drug resistance, or toxicity within 8-9 months of 
treatment.1,5 Yet, current evidence to aid in clinical decision making is limited.60-62   
D.1. Drug efficacy, effectiveness, and safety 
Current guideline recommendations are based solely on evidence provided by phase II 
and III clinical trials. A schematic of the NCCN guidelines for recommend therapies for mRCC 
are presented in Figure 4.11 Trials are needed to demonstrate drug safety and efficacy; however, 
these studies are designed such that experimental treatments must be compared to the best 
current standard of care.63 Because many drug trials for mRCC were conducted around the same 
time, experimental treatments were compared to interferon-α, the standard of care at the time. 
Therefore, there are few head-to-head trials conducted between different treatments such as 
sorafenib, sunitinib, and pazopanib predominantly.36,43,47,64-69  More recently approved treatments 
such as the combination of nivolumab and ipilimumab were compared to sunitinib, which 
became the standard of care in 2009.  
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Figure 4. 2017 recommendations for relapse of Stage IV and surgically unresectable kidney 
cancer.11 
 
 Generalizability of trial evidence pose another challenge for determining drug 
effectiveness. It is estimated that fewer than 1 in 20 adult cancer patients enroll in cancer clinical 
trials.70 Further, cancer clinical trials tend to underrepresent older adults (65+ years), women, 
racial minorities, and patients of lower socioeconomic status.70-73 Other barriers to trial 
participation include access to cancer clinics participating in trials, narrow eligibility criteria, 
physician and patient attitudes towards trial vs. existing standard of care.74 Each treatment is also 
associated with different adverse events, which may influence their use and duration in the  real 
world.1,75 Therefore, trial results may also not be reflective of patients treated in clinical practice. 
To illustrate this, a study of mRCC patients in German routine care showed trial-ineligible 
patients had overall inferior outcomes compared with potentially trial-eligible routine patients.76 
Yet, at least 60% of all patients included in the study would be ineligible for participation in 
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RCTs, including those with brain metastasis.76 In the real world, older adults, in particular, may 
be more likely to experience poorer outcomes compared to younger, trial-eligible patients 
because they may be more susceptible to adverse drug effects because of higher comorbidities, 
greater sickness or frailty. Comparative effectiveness studies to assess clinical outcomes such as 
disease progression and survival have been used to fill this evidence gap. However, most studies 
have compared effectiveness between sunitinib and pazopanib.  
D.2. Treatment utilization and sequencing  
Given the evolving landscape, understanding utilization of these treatments over time in 
routine clinical setting can provide invaluable insight to care delivered to these patients, 
especially when comparative effectiveness research is limited. Yet, there are few studies that 
comprehensively evaluate the patterns of utilization of mRCC treatment. Studies assessing 
utilization and impact of mRCC treatment often focus on the use of selected treatments, 
predominantly sunitinib and pazopanib, thus providing a limited picture of what is occurring in 
routine clinical practice.41,77-80 For example, a global retrospective study conducted in 
community oncology clinics in the US, Europe and Asia only assessed first- and second-line 
treatment of sunitinib, sorafenib and bevacizumab78 while another study of elderly mRCC 
patients only included those patients who initiated pazopanib or sunitinib.41,77  
Moreover, several existing treatment patterns studies are based on retrospective medical 
chart reviews, where selected physicians extract clinical information from chart reviews on a 
random sample of their own patients. Because of the case-sampling method for this study design, 
findings from these studies may not truly be reflective of the real-world use of mRCC 
treatment.78,81  For example, in one study, 36 US physicians from a nationwide oncology 
network who had at least five mRCC patients under their care in 2011 were identified and asked 
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to select up to 15 sequential patient charts meeting the study inclusion criteria . Results from this 
study showed sunitinib was the most common first-line therapy.81 While this was consistent with 
other studies, patterns of treatment described in these types of studies are reflective of treatment 
decisions made by the physicians selected into the study and their patients, and therefore, may 
not be generalizable. 
Of the few comprehensive mRCC treatment utilization studies, variation in first- and 
second- line therapy treatment has also been shown. For example, Miller et al. conducted a 
claims-based study to describe patterns of treatment associated with systemic therapies in mRCC 
patients. mRCC patients were identified in the Humana database, which is comprised of a single 
commercial payer system between 2007 and 2013, mRCC. Results from this study showed that 
the most commonly prescribed drug for first-line treatment was sunitinib (43.9%) followed by 
sorafenib (14.0%), temsirolimus (14.8%), pazopanib (10.0%), bevacizumab (9.4%), everolimus 
(4.9%), IFN (2.3%), aldesleukin (<1%), and axitinib (<1).82 This study also showed that 
clinicians generally followed NCCN guidelines for first-line treatment (e.g., sunitinib, 
pazopanib, and bevacizumab with IFN), but, everolimus, not approved for first-line mRCC, was 
prescribed to 5% of patients.82 More recently, another treatment pattern study in mRCC was 
conducted by Pal et al.83 mRCC patients were identified between 2011 and 2015 in Marketscan. 
Similar to findings by Miller et al., the most common first line agent was sunitinib (43%); 
however, the distribution of treatment was substantially different with the second highest 
prescribed treatment being pazopanib (32%), temsirolimus (8%), bevacizumab (7%), everolimus 
(4%), sorafenib (3%), and axitinib (3%). While these existing evidence are provide insight to the 
delivery of care in patients initiating first line treatment, they only reflective of the care received 
by patients with commercial health insurance up to 2016.  
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Trial and observational studies exploring treatment sequencing are also lacking. Optimal 
treatment sequences to improve health outcomes poses another major challenge for clinicians 
and patients because most patients who initiate first-line targeted therapies often require a 
second-line agent due to treatment failure, drug resistance, or toxicity. Despite various treatments 
approved for second-line treatment, there is limited guidance or recommendation for which 
treatments are most effective or in what order they should be administered. Until 2015, 
guidelines for second-line therapy after first-line TKI were based on two phase III trials.84  
Further results from one observational study conducted by Miller et al showed, 37% of patients 
on first-line therapy switched to a second-line agent, and were treated with everolimus (29%), 
bevacizumab (20%), temsirolimus (16%), sunitinib (14%), pazopanib (12%), and sorafenib 
(10%).82 On the otherhand, a more recent study conducted by Pal et al showed more patients 
(52.8%) received 2L treatment, with most patients similarly receiving everolimus, followed by 
axitinib and nivolumab.83 Given this knowledge gap, there is wide variation in selection of 
second-line treatment.  
Observed differences between these studies also underscore the evolving treatment 
landscape for mRCC patients. Thus, studies evaluating temporal changes in utilization of mRCC 
treatment are also needed to understand delivery of clinical care and outcomes over time. For 
instance, a prospective study was conducted between 2007 through 2017 in a German clinical 
cohort of mRCC patients. Similar to previously cited studies, results from this study showed the 
most frequently used first-line treatment was sunitinib, with nearly 50% of the patients receiving 
the TKI.76 However, evaluation of temporal changes in utilization showed declines in 
prescriptions of sunitinib treatment in favor of pazopanib. In 2007 to 2009, the most frequently 
used second-line treatments were sorafenib, temsirolimus, and sunitinib, yet from 2010 through 
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2015, most patients were treated with the mTOR inhibitor everolimus, followed by sunitinib and 
pazopanib.76 However, this study was conducted in a German population and may not be 
generalizable to the studies in the United States, as there substantial differences between 
healthcare systems.  
With a wide variation in selection of first- and second- line treatment over time, there is 
great uncertainty of how mRCC treatment are utilized in routine clinical practice. Existing data 
are limited and are only reflective of the care received by specific patient populations. Some 
studies are also more prone to selection bias. Therefore, more studies are needed to elucidate 
historic and contemporary treatment utilization in broader populations. Given this knowledge 
gap, carefully designed claims-based studies can be used to address the quality of care delivered 
to mRCC patients. However, various considerations are needed to reduce potential bias and 
improve study validity when selecting patient populations in this data, especially in the 
metastatic setting.  
E. Claims data to identify incident metastatic renal cell carcinoma  
Administrative claims and other routinely collected data provide the foundation for many 
drug utilization, safety, and effectiveness studies as these databases provide a rich source of 
timely healthcare information on large, well-defined populations. Claims data captures detailed, 
longitudinal information on diagnoses, procedures, medications, and healthcare visits for well- 
defined patient populations in routine clinical practice. Yet, information contained in these 
databases is generally coded using standardized systems, summarizing complex medical 
histories, clinical diagnoses, and services and therapies provided to patients. Because claims data 
are generated for billing and not research purposes, they often lack clinical detail that can hinder 
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study validity. For instance, cancer metastases may be identified using diagnosis codes, but their 
accuracy has been shown to be low and vary by tumor type.85   Several validation studies have 
evaluated the accuracy of claims-based definitions to identify incident cancers in breast, 
lymphoma, and lung cancer and have reported substantial missclassification.85-87  
Claims-based studies of mRCC patients require the presence of at least 2 claims with a 
primary diagnosis for RCC (International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9): 189.0, 189.1 and at least 1 claim with a diagnosis of metastatic disease 
(ICD-9: 196.xx-199.xx) has been used to identify cases of mRCC (Table 2). Yet, to date, no 
study has developed or validated incident mRCC in claims data. Given the low incidence of 
mRCC and the potential for misclassification using diagnoses codes alone, a carefully designed 
validation that evaluates the accuracy of coded algorithms to identify incident mRCC against a 
reference standard will be an essential component for optimizing the use of these data for this 
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F. Adherence and persistence to oral targeted therapies in mRCC patients.  
Medication taking behavior poses another unique challenge in clinical practice. More 
therapies are now orally administered in the home, raising concerns about (1) medication 
adherence, the extent to which a patient acts in accordance with the prescribed interval and dose 
of a dosing regimen, and (2) persistence, the duration of time from initiation to discontinuation 
of therapy. 
Prior to the development of oral therapies, patients with cancer had to receive intermittent 
intravenous (IV) therapy administered by a nurse in a controlled and observable setting. Regular 
infusion sessions enabled more frequent monitoring for toxicity and side effects, drug 
interactions and therapeutic response, and opportunities for educating patients about their 
treatment by a trained medical professional. 95,96 Since the advent of oral anti-cancer therapies, 
several studies, predominantly among breast cancer patients, showed patients preferred oral over 
IV treatment so long as the treatment does not reduce efficacy or increase drug toxicity.97-99 
Reasons for preference for oral treatment included convenience and ability to receive treatment 
at home, thus requiring fewer clinic visits and more flexibility in timing and location of 
administration. They are also easily administered and non-invasive.  
The shift in treatment paradigm from IV to oral administration of chemotherapeutic 
agents has also resulted in a shift in the responsibility of drug acquisition and administration 
from a trained medical worker to the patient and their caregivers.100 Yet, patients, particularly 
those who are very sick or elderly, may have difficulty managing their own treatment, potentially 
affecting their adherence and persistence to treatment. Studies have shown that the complexity of 
many oral anticancer regimens and difficulty managing their side effects in the home are 
associated with suboptimal adherence.96,101 Several factors including age, race, comorbidities, 
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initial dose, utilization of medical care, and cost were also shown being correlated with poor 
adherence.84 Moreover, medication non-adherence and non-persistence have been shown to 
reduce drug efficacy, potentially resulting in dosing errors, unnecessary alternative therapies, 
treatment failure, or premature discontinuation of therapy.102 Ultimately, non-adherence and non-
persistence may lead to worse health outcomes and increased risk of adverse events. This is 
especially concerning for patients with metastatic disease as oral TTs are more often used. 
Patients treated in the metastatic setting are simultaneously more likely to be frail and have 
higher risks of toxicities.103 Especially given the rapid increase in drug approvals for oral TTs 
along with emerging combination regimens for metastatic disease, non-adherence to oral 
therapies is an emerging issue in the metastatic setting. 
There are several existing studies evaluating adherence and non-persistence to oral 
anticancer treatments. A recent systematic review reported wide variation in rates of adherence 
to oral antineoplastic therapies, ranging from 46% to 100% in various tumor types, including 
breast, prostate, colorectal, and lung cancer.84 However, there is a critical gap in knowledge in 
regards to medication adherence and non-persistence in the metastatic setting, as most published 
studies were conducted in patients with localized disease.74,84,104-110 Patients with metastatic 
disease are often excluded from the study or represent a small proportion of the study 
population.111,112 Yet, due to more effective treatment options, more patients with metastatic 
disease experience longer survival and improved prognosis. Thus, there is growing need to 
understand medication taking behavior in this patient population.  
Claims-based approaches to calculating measures of adherence and persistence utilizes 
prescription data: drug name, the days’ supply, and date filled. However, careful consideration of 
how these measures are defined are needed in the metastatic setting due to high mortality in the 
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population. Table 3 presents the five-year survival rates by stage at diagnosis in the US for 
various cancers, including kidney. For cancers with low survival rates, death is a major 
competing risk for adherence and persistence.  However, there is no guidance for calculating 
these measures while accounting for mortality. 
 
Table 3. Five-year Relative Survival Rates* (%) by Stage at Diagnosis, US, 2008-201475 
 
The two most common claims-based approaches to estimating adherence is calculated 
using either the medication possession ratio (MPR) or proportion of days covered (PDC), where 
adherence is reported as a percentage, generally an 80% threshold. 113 However, assessment of 
adherence studies to oral anticancer drugs showed wide variation in how studies accounted for 
death. Most often, studies will explicitly exclude patients who die within the study period, or 
more commonly, they will require continuous enrollment post-treatment to implicitly exclude 
those who die. Some studies may report adherence at various time points and only include those 
who survived up to those times in their calculation, thus changing the study population at each 
time. While other studies will include patients who die but they may define any time after death 
as non-adherent, therefore assigning time after death as a PDC or MPR =0.  Another frequent 
approach is defining the MPR as the number of days supplied divided by the total time on 
treatment.82 Meaning that patients who die are not excluded from the study and time after death 
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is excluded from the denominator because death is counted as a discontinuation.82,88 Despite 
many approaches to potentially navigating death, most studies do not report the number of deaths 
in their results section or discuss the implications of how they handled death on their estimates of 
adherence. Table 4 shows adherence definitions and handling of death in adherence studies for 
different cancer types.  
Wide variation in calculating and reporting persistence while accounting for death was 
also observed across studies. A summary of persistence studies conducted in patients with 
metastatic disease are presented in the Table 5.  Persistence is generally defined as the time from 
treatment to initiation to treatment discontinuation. It is also most often reported as a 
dichotomous value of yes or no or presented as a mean or median time to discontinuation. Some 
studies may also report persistence as a cumulative proportion using Kaplan Meier methods. 
Like many adherence studies, patients who died are often excluded from the study. However, 
some studies include death in their treatment discontinuation definition. In other words, death is 
placed into the same category of treatment switches, treatment failure, etc. Studies interested in 
in the risk of discontinuation over time will also often censor death, which may overestimate the 
risk of discontinuation.  
Given the various designing and analyzing studies of medication adherence and 
persistence in metastatic cancer populations and their potential implications for study validity, 
further exploration of measuring adherence and persistence in the presence of death as a 







Table 4. Adherence to oral anticancer studies  
Author Cancer type Stage Data Source Type Handling of death  Measured Estimate 
McCowan 
(2008) Breast All Stages 
National Healthcare 
database Censored 
MPR ≥ 80:  : total days 
supply/time on treatment 83% 
Kimmick 
(2009) Breast 
Early Stage only 
(I-III) 
Cancer registry -
claims No discussion 
MPR ≥ 80: total days supply/(365 
days - hospital days) 75% 
Hershman   
(2010) Breast Early Stage only 
Electronic Health 
Record linked to 
cancer registry  Included in denominator 
4.5-year MPR >80% total days 







MPR ≥ 80:  total days 








MPR ≥ 80: total days supply/time 
on treatment 69% 
Makubate 
(2013) Breast All Stages 
National Healthcare 
database Censored 
MPR ≥ 80:  : total days 
supply/time on treatment 90% 
Weaver  
(2013) breast 
Early Stage only 
(I-III) Claims-Death 
Exclusion: Patients who 
died within a year after 
start of therapy 
MPR ≥ 80: total days supply/time 
on treatment 46%-63% 
Hsiwh  
(2014) Breast 
Early Stage only 
(I-III) Claims  Censored 
MPR ≥ 80: total days supply/time 
on treatment 77.30% 
Sedjo  
(2014) Breast All Stages Claims  No discussion 
1-year MPR >80%: total days 
supply/(365 days) 77% 
Trabulsi  
(2014) Breast 
Early Stage only 
(I-III) 
National Healthcare 
database No discussion 
MPR ≥ 80: total days supply/time 
on treatment 83.50% 
Neuner 
(2015) Breast All Stages Claims 
Time after death 
excluded 
PDC ≥ 80:  total days 









(2016) Breast All Stages Claims 
Time after death 
excluded 
PDC ≥ 80:  total days 




Early Stage only 
(I-III) Claims 
must be alive for at least 
1-year after  
PDC ≥ 80:  total days 
supply/Fixed time interval (365 
days) 63% 
Stokes 
(2017) Various All Stages Claims 
Assumed Lost to 
follow-up 
MPR ≥ 80:  : total days 
supply/time on treatment 56%-72% 
Behl 
(2018) Prostate Stage IV Claims No discussion 
MPR ≥ 80:  : total days 









PDC ≥ 80:  : total days 
supply/Total follow-up 79% 
Zhao 
(2018) Breast All Stages Registry-claims Excluded 
PDC ≥ 80:  total days 
supply/Fixed time interval (365 
days) 67% 
Benegas  
(2019) CML All Stages 
Electronic Health 
Record  Discontinuation 
PDC ≥ 80:  : total days 
supply/time on treatment 85%-94% 
Farias 
(2019) Breast 
Early Stage only 
(I-III) Claims  No discussion 
PDC ≥ 80:  total days 
supply/Fixed time interval (365 
days) 74% 
Patel  
(2019) Colorectal Metastatic Claims  No discussion 
MPR ≥ 80:  : total days 
supply/time on treatment 72%-87% 
Patel  
(2019) Colorectal Metastatic Claims  No discussion 
PDC ≥ 80:  : total days 




Early Stage only 
(I-III) 
Electronic Health 
Record  No discussion 
MPR ≥ 80:  : total days 
supply/time on treatment 80% 
Sheppard  
(2019) Breast 
Early Stage only 
(I-III) 
Electronic Health 
Record  No discussion 
PDC ≥ 80:  total days 








Table 5. Non-persistence to oral anticancer studies 
Author Cancer type Stage Data Source Type Handling of death  Measured Estimate 
Barron (2007) Breast All Stages 
National Healthcare 
database Censored 
1- year cumulative incidence-
KM curve 22.10% 
McCowan (2008) Breast All Stages 
National Healthcare 








claims No discussion 1-year Dichotomous (yes/no) 80% 
Hershman  (2010) Breast 
Early Stage 
only (I-III) 
EHR - cancer 







2-year cumulative incidence 
proportions 50% 




database Exclusion Kaplan-Meier 12% 
Weaver (2013) breast 
Early Stage 
only (I-III) Claims-Death Exclusion 
1-year MPR >80% 
1-year persistence contin 82% 
Hsiwh (2014) Breast 
Early Stage 
only (I-III) Claims  Censored Dichotomous (yes/no) 85% 
Biggers (2016) Breast All Stages Claims 




Stokes (2017) Various All Stages Claims 
Assumed Lost to 
follow-up 
MPR ≥ 80:  : total days 
supply/time on treatment 
161.8 days - 
186.2 days 
Behl (2018) Prostate Stage IV Claims Discontinuation Dichotomous (yes/no) 93%-46% 
Gao (2018) Breast 
Early Stage 
only (I-III) Hosptial data Discontinuation Proportion competed treatment 63.1 
Zhao (2018) Breast All Stages Registry-claims Excluded Median 659 days 
Patel (2019) Colorectal Metastatic Claims  No discussion Dichotomous (yes/no) 32%-39% 
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CHAPTER 3: METHODS 
A. Overview  
The objective of the proposed research is to explore methodological considerations for 
leveraging large healthcare databases to fill a critical gap in knowledge in the evolving landscape 
of targeted therapeutics for mRCC. We will focus on the period from 2007-2016, an era where 
multiple new TTs were approved for use in mRCC.114 We first aim to develop algorithms to 
identify individuals newly diagnosed with mRCC using claims data alone. These databases 
capture detailed, longitudinal information on diagnoses, procedures, and medications from 
healthcare encounters for well-defined patient populations in routine clinical practice. 
Algorithms will be developed and validated using the cancer registry and healthcare claims 
linked database.   These algorithms will enable future researchers to leverage a variety of large 
healthcare claims databases to investigate the use of mRCC treatment, for which there is little 
existing evidence.  
In our second aim, we will examine adherence and persistence to oral TTs in patients newly 
diagnosed with mRCC. This aim will explore the impact of mortality on adherence and 
persistence measures by comparing various approaches to their estimation.   Death is a major 
competing risk in the metastatic setting. However, studies evaluating adherence in the metastatic 
setting are few, and of existing adherence studies in oncology, death as a competing risk has 
neither been explored nor discussed.  
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This research protocol was approved by the Institutional Review Board and the Office of 
Human Research Ethics at the University of North Carolina.  
B. Data sources 
For this research, we used data from the SEER-Medicare linked database. The National 
Cancer Institute’s SEER program is a surveillance system collecting demographics, clinical and 
tumor data, selected treatments, vital status, and cause of death for all individuals diagnosed with 
cancer within one of 18 SEER regions, currently covering 34.6% of the cancer population in 
US.115 SEER-Medicare represents a linkage of persons in SEER with their Medicare enrollment 
and claims data including >3.3 million individuals. 
Medicare is a federally funded program that provides health insurance for the elderly, 
persons with end-stage renal disease, and some disabled. For persons age 65 and over, 97 percent 
are eligible for Medicare. Almost all Medicare beneficiaries have Part A coverage that includes 
hospital, skilled-nursing facility, hospice and some home health care. Part B coverage includes 
physician and outpatient services. Overall, 67 percent of Medicare beneficiaries are enrolled in 
Medicare Part A and B.116 Medicare Part C refers to HMO enrollment. While some Medicare 
beneficiaries are enrolled in HMOs, most have fee-for-service (FFS) coverage; however FFS 
enrollment varies over time and by region.116 The Medicare Part D program provides 
prescription drug coverage for beneficiaries who purchase this benefit. For this proposed 
research, we will restrict analyses to individuals with Medicare Parts A, B, and D coverage 
residing in non-SEER regions to prevent patients from appearing in more than one dataset.   
The database includes cancer cases through 2015 and Medicare claims through 2017. 
Claims provide data on service dates, diagnoses, and procedures and prescription dispensing 
(since 2007). For the proposed study, we will draw upon two cohorts of people included in the 
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SEER-Medicare data - persons with cancer and a 5% random sample of Medicare beneficiaries 
who do not have cancer, but reside in a SEER region.115  
C. Aim 1 Approach 
We will develop algorithms to identify incident mRCC patients in claims data alone. To develop 
and validate these algorithms, we will use the SEER-Medicare linked database. 
C.1. Study Population  
C.1.1. Patients with mRCC.  
 Using SEER, we will identify all incident mRCC cases using the International 
Classification of Disease for Oncology, Third Edition (ICDO-3) site code: C64.9 and histology 
codes indicative of RCC 8120-8131, 9050-9055, 9140, 9590-9992 from 2006-2015. with at least 
one of the following classifications according to the AJCC TNM 6th Edition staging system to 
indicate metastatic disease: stage IV or M1, or distant according to the SEER summary stage. 
Patients missing stage or who were diagnosed at death or autopsy were excluded. Because the 
SEER program only collects the month and year of diagnosis; there is no exact diagnosis date. 117 
We will define the diagnoses date for the SEER-Medicare population as the the first day of the 
month of diagnosis in SEER.  
C.1.2. Non-mRCC patients.  
  We will include all persons identified in the 5% random sample of non-cancer patients in 
SEER-Medicare. The "non-cancer" group is drawn from a random 5 percent sample of Medicare 
beneficiaries residing in the SEER areas. Persons in the 5 percent sample who also appear in the 
SEER data are removed from the 5% non-cancer database, leaving a sample of non-cancer 
cases.115 However, within the SEER data, cancer patients identified in the 5% random sample a 
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flag is created for these patients. For this study, all non-mRCC cases will be comprised of 
individuals who were identified in the 5% random sample, which will include individuals 
without any cancer and patients diagnosed with other cancers including stage I-III RCC.   
C.1.3. Enrollment criteria.  
  We will require all individuals to have continuous coverage in Medicare Parts A, B, and D 
for at least 10 months. The rationale for 10-month windows was to account for symptoms and 
clinical diagnostic work-up occurring within 6 months prior to an mRCC diagnosis and 
subsequent initiation of treatment or death within 4 months after the diagnosis. Because 
Medicare Part D data is unavailable in SEER-Medicare until January 1, 2007, to ensure that all 
cases had a 6-month look-back period to assess diagnostic work-up prior to their month of 
diagnosis for mRCC cases, all individuals (both cancer patients and those without cancer) will 
begin contributing observed time starting July 1, 2007 or start of insurance enrollment and other 
eligibility criteria. 
C.2. Observation windows.  
   Ten-month continuous enrollment windows were created for each individual, advancing 
in 1-month increments from the start of their eligible Medicare enrollment start date until the end 
of follow-up, death, or disenrollment, whichever came first. This approach will allow those with 
and without mRCC to contribute more than one period of observation. An illustration of 
observation windows created for an individual over time is presented in Figure 5. In this figure, 
a subject is enrolled on Jan. 1, 2007, and his/her first window is created once they have had at 
least 10 months of continuous enrollment. Thus, their first observation window begins on Jan. 1, 
2007 and ends on Oct. 31, 2007. Advancing forward to the next month, the second observation 
window for this subject begins on Feb. 1, 2007 and ends on Nov. 30, 2007, and so forth until the 
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patient is loss to follow-up or disenrollment. Windows with less than 10 months are excluded, 
unless an individual dies within 4 months after the 6 th month within each window. More details 
for how death is handled is described in later sections of this document. 
 
Figure 5. Example of 10-month enrollment windows belonging to one subject. Each window 
advances in 1 month increments until loss to follow-up or disenrollment. 
 
  The rationale for incorporating multiple observation windows that advance over time 
for each individual is to allow cases to move in and out of the cohort. There are periods of time 
in which cases are “cancer free” prior to their diagnosis. During these periods, claims data a re 
more representative of true non-cases. There are also periods of time after diagnosis, where 
claims data are more representative of prevalent and not incident cases.  This approach accounts 
for changes in cancer status over time by allowing cases to contribute observation time prior to 
becoming a case and excluding observation time occurring after becoming a case. Thus, mRCC 
case and non-case status will be defined for each observation window.  
C.2.1. Observation windows belonging to mRCC patients 
   Each case will contribute multiple windows of non-case status until observation 
windows overlap with the month of diagnosis. However, because information 6 months prior to 
through 4 months after the diagnosis is needed to ascertain case status, only  one window for each 
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mRCC patient will meet this criteria. Windows belonging to mRCC patients will therefore be 
defined as: (1) referent mRCC windows, (2) almost case windows, (3) prevalent case windows, 
and (4) non-case windows. The index date for referent mRCC windows will be assigned the 
diagnosis date which is also the 1st day of the 7th month within the case window. To be 
consistent, we will assign the index date as the 1 st day of the 7th month for all other windows 
  Referent mRCC windows. The true mRCC referent window will be defined as a window 
belonging to an mRCC patient that has 6- months pre- through the 4 months or death post-cancer 
diagnosis. Further details about patients who died prior to 4 months after diagnosis is provided 
below. Six-month pre-cancer diagnosis was chosen to account for the clinical diagnostic work-up 
period prior to cancer diagnosis and the 4- month post-cancer diagnosis was chosen to ensure full 
capture of patients who may receive any treatment for mRCC. A schematic illustrating the 
referent mRCC window and when diagnostic work up and treatment relative to the diagnosis 




  Almost mRCC window status. Almost case status was assigned to windows that included 
up to 6 months prior to the date of diagnosis, but did not include the date of diagnosis itself. 
Figure 6. Referent mRCC case window 
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These were considered almost case windows because they potentially included information 
related to symptoms and diagnostic work up for mRCC diagnosis. Therefore, these windows are 
not reflective of a true non-case window. A schematic of almost case windows are presented in 
Figure 7.  
 
 
  Prevalent window status. All windows occurring after the mRCC referent case window 
will be classified as prevalent case windows and were excluded from the analysis.  
  Non-case window status. All other windows belonging to an mRCC case occurring before 
almost case windows were classified with non-case status. These windows do not include the 
date of diagnosis or the critical period of time for evaluating diagnostic work-up or symptoms 
related to mRCC diagnosis. Therefore, these windows were determined to be similar to those 
belonging to individuals never diagnosed with mRCC (Figure 5). 
Figure 7. Almost case windows 
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  Excluded windows. All observation windows that included the month of diagnosis that do 
not contain all the information needed to ascertain case status were excluded. More explicitly, 
these were windows that had less than 4 months of continuous enrollment after diagnosis or less 
than 6 months of continuous enrollment prior to the index date. A detailed example of 
observation window status changing over time for a patient diagnosed with mRCC is presented 
in Figure 8.  
 
Figure 8. Example of changing case status with moving time windows for a hypothetical 
case diagnosed at month 16. Case will have non-case status for each month from the start 
of enrollment until the 10-month observation period overlaps with the month of diagnosis 
(Months 1-7). Cases status will be excluded for windows beginning in months 6 through 9 
and months 11 through 16. These windows overlap with the month of diagnosis, however 
there is not enough information within these windows to ascertain case status. Only the 
window beginning in month 10 will be a true case. Windows that begin after the month of 




 Patients who died within 4 months of diagnosis. Because mortality is high and short 
term, many patients did not survive through the 4 months after diagnosis. To ensure capture of 
case information for these patients, we will relax the 4 month post-month of diagnosis 
requirement and allow patients to contribute follow-up time until the month of death. Thus, case 
windows for patients who die will have a shorter observation time (Figure 9).  
 
 
Figure 9. Continuous enrollment period for cases who die within 4-months after the month 
of diagnosis. All cases are still required to have continuous enrollment for 6 months prior 
to the date of diagnosis, but are only required continuous enrollment up to the month of 
diagnosis. 
 
Observation windows belonging to individuals without mRCC 
  Each non-case can contribute multiple windows of non-case status until loss to follow-up 
or end of study period. Figure 10 shows only an index date and continuous enrollment. For a 
true non-case window, there should be no evidence of symptoms/diagnostic work up, diagnosis 





Figure 10. 10-month enrollment window for non-case windows. The index date is assigned 
to the 1st day of the 7th month to be consistent with the timing of the mRCC diagnosis date 
occurring in the referent mRCC case windows. 
 
C.3. Outcome assessment: Identifying incident mRCC 
C.2.1. mRCC gold standard.  
  Using cancer registry data, we will define the gold standard for true incident mRCC 
cases as those diagnosed with a primary RCC who are classified as stage IV or M1 according to 
the AJCC TNM 6th Edition staging system or distant according to the SEER summary stage. 
C.2.2. Algorithms.  
 We will construct the two types of algorithms to identify incident mRCC in claims data. 
• Algorithm 1. Similar to “Definition 2” developed by Setoguchi et al, we will use 
ICD-9 diagnosis codes only identified in inpatient and outpatient claims to classify 
incident mRCC cases.86 mRCC will be defined as having one or more primary or 
secondary diagnosis codes for metastatic disease (ICD-9: 196.xx- 199.xx) and 2 or 
more diagnosis codes for cancer of the kidney (ICD-9: 189.0) on any inpatient or 
outpatient claim within 60 days. 
• Algorithm 2. Similar to “Definition 1” developed by Setoguchi et al, with clinical 
input, we will also use ICD-9, HCPCS, and CPT codes to develop a clinically-derived 
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algorithm that reflects the pathway for diagnosing and treating mRCC to classify 
metastatic cases (Appendix 4). The timing for identifying these variables within case 
and non-case windows are defined in Figure 11.  
 
 
Figure 11. Timing of diagnosis codes, diagnostic work up, symptoms, treatment, and death 
related to mRCC diagnosis 
 
C.4. Candidate predictors of metastatic RCC. 
 We used the 2017 NCCN and clinical input to identify variables potentially predictive of 
metastatic RCC status. We will include diagnostic and procedure codes indicating symptoms, 
diagnostic work-up or treatment of metastatic RCC. This includes codes for imaging, blood tests, 
surgery, chemotherapy, neoplasm in the lung, lymph nodes, bone, liver or brain, symptoms 
related to mRCC and codes and encounters indicating palliative and hospice care. Diagnostic and 
procedure codes will also be used to rule-out patients with localized or recurrent disease. For 
instance, patients previously treated other chemotherapies or had a partial nephrectomy prior to 
having an ICD-9 code for metastatic disease.  
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 All variables will be defined using Current Procedural Terminology (CPT) codes, 
Healthcare Common Procedure Coding System (HCPCS), ICD-9 diagnosis and procedure codes, 
and National Drug Codes (NDC) listed in claims from the 6-months before through the 4-months 
following the month of diagnosis (Appendix 5 and 6). In addition to these variables, we will 
stratify algorithms by age, sex, race, and region.  
C.5. Statistical Analyses 
C.5.1. Validation of claims-based algorithms in SEER-Medicare.  
  We will calculate sensitivity (the proportion of true positives captured by the 
algorithm); specificity (the proportion of true negatives classified as a non-case); positive 
predictive value (PPV) (the probability that an individual is a true case given the algorithm calls 
an individual a case); and negative predictive value (NPV) (the probability the person is not a 
true case given the algorithm classifies an individual as a non-case), and corresponding 
bootstrapped 95% confidence intervals in all cohorts.  
C.5.2. Sensitivity analyses.  
 In a sensitivity analysis, we will extend the post-cancer diagnosis window to 6 months 
to include those who may have received delayed treatment. In addition, given that approximately 
25%-33% of patients with localized disease will have a recurrence within 1-2 years after 
receiving surgical treatment, we will conduct another sensitivity analysis extending the look back 
period to one to two years prior the month of diagnosis to identify and exclude those who 
received a nephrectomy and may be a recurrent case. Because the algorithm conditions on 
treatment after the diagnosis of mRCC occurs, the algorithm may miss those who died before 
they were able to receive treatment. We will thus conduct a sensitivity analysis to develop an 
algorithm that only uses information in the 6-months and 1-year prior to the date of diagnosis.  
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D. Aim 2 Approach 
Compare approaches for measuring medication-taking behavior in high-mortality populations, 
such as patients diagnosed with mRCC.  
 
D.1. Study Population  
  Incident mRCC will be identified in the SEER-Medicare using cancer registry data from 
2007-2013. Patients missing stage as defined by the AJCC TNM 6th Edition staging system 
(stage IV), SEER summary stage (distant), and any metastasis according to the TNM staging 
system (M1) or diagnosed at autopsy or by death will be excluded. The diagnosis date for cases 
identified in SEER-Medicare will be defined as the first day of the month diagnosed in SEER. 
All individuals must have continuous insurance coverage for the 6-months pre- through the 4-
months post-cancer diagnosis for identification of potential predictors of metastatic disease. 
Patients who die within the 4 months after diagnosis will not be excluded from the study.  All 
cohort members will be followed until death, plan disenrollment, or study period end. The final 
study population will be limited to patients with incident mRCC who initiated an oral first-line 
TT. All TTs for mRCC are orally administered except temsirolimus and bevacizumab in 
combination with IFN which are administered through an IV. The first claim for TT will 
correspond to the index date. Patterns of TT use will be defined using subsequent dispensing data 
(i.e., dispensing date and days’ supply).  
D.2. Outcome assessment: Adherence and Persistence to oral targeted therapies and Mortality 
D.2.1. Persistence  
Persistence to TT will be quantified as the time from treatment initiation to treatment 
discontinuation. Patients will be defined as persistent to therapies if the duration of one cla im 
overlaps with the date of a subsequent claim. A 30-day grace period will be introduced between 
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successive prescription claims to allow for delays in regular refilling. Treatment discontinuation 
will be considered as a switch to a different TT (second-line therapy initiation) or if a patient 
does not have a subsequent claim for a TT by the end of the days’ supply plus the grace period 
(i.e., discontinuation). For patients who switch to a new therapy, their discontinuation date will 
be defined as the date of second line treatment initiation. The end of the last days’ supply will be 
the discontinuation date for those who do not have a subsequent claim after the  grace period. To 
evaluate the impact of mortality on measures of persistence, death will be treated as a 
discontinuation, a censoring event, excluded from the analysis, or as a competing risk. The date 
of discontinuation due to death will be defined at the date of death. If a patient dies during the 
grace period, that discontinuation will be considered a death. Examples of persistence is 
described in Figure 12 and Figure 13.  
Month 1 2 3 4 5 6 7 8 9 10 11 12 
First-line therapy 
(30-day supply)                         
Figure 12. Example 1: Treatment discontinuation 
 
  In Example 1, persistence to first-line therapy is 8 months. There is a 30-day delay in 
month 5. Because there is a claim within the 30 day grace period (shown in month 6), the patient 
remains persistent through the entire 8 months. There are no subsequent refills within the 30-day 
grace period after month 8. Thus treatment discontinuation is defined at month 9.  
Month 1 2 3 4 5 6 7 8 9 10 11 12 
First-line therapy (30-
day supply)                         
Second-line therapy 
(30-day supply)                         
 
Figure 13. Example 2: Treatment discontinuation.  
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In this Example 2, persistence to first-line therapy is 6 months because there are no 
subsequent fills after the 30 day supply is completed at month 6 plus the grace period. There is 
also a drug switch at month 8. 
D.2.2. Adherence 
Adherence will be calculated using the proportion of days covered (PDC) typically 
defined as the number of days covered by therapy divided by the total days of follow-up over a 
specified period of time.118 The number of days will be based on the prescription fill date and 
days’ supply. For those with overlapping prescription fills for the same drug, we will shift the 
second overlapping prescription forward to begin at the end of the days’ supply for the previous 
prescription. An example of this is shown in Figure 14.  
 
 Month 1 2 3 4 5 6 7 8 9 10 11 12 
First-line therapy drug 
A (30-day supply)                         
First-line therapy drug 
A (30-day supply)                        
Proportion of days covered (PDC):  
   Days supplied: 300 (10 months) 
   Follow-up time: 365 days (12 months) 
   PDC = (300)/(365) = 0.82 
Figure 14. Example 3. Overlapping fills for the same therapy 
In this example, there is an overlap in 30-day supply on month 8. We will shift this 2nd 
prescription fill on month 8, one month over, so the coverage of days supply will extend through 
month 11. In this example, there is also a gap in month 5. The prescription is filled within the 30 
day grace period, so the patient will remain persistent to the drug during this time. However, the 
patient will not be defined as adherent, and this month will only contribute to the follow-up time.   
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For those with overlapping fills for two different mRCC treatments due to a treatment 
change, no adjustment will be made as first and second-line adherence and persistence will be 
evaluated separately. An example is presented in Figure 15. In this example, there are 
overlapping fills of the first- and second- line treatments in month 8. Adherence for first-line 
therapy will be calculated beginning in month 1 of the first prescription fill for a first-line drug 
through the 8 months. Adherence for second-line therapy will be calculated in the beginning in 
month 8 through the end of this example follow up time in month 12. 
 
Month 1 2 3 4 5 6 7 8 9 10 11 12 
First-line therapy (30-
day supply)                         
Second-line therapy 
(30-day supply)                        
1st-line:  
Proportion of days covered (PDC):  
   Days supplied: 210 (7 months) 
   Follow-up time: 240 days (8 months) 
   PDC = (210)/(240) = 0.875 
2nd-line:  
Proportion of days covered (PDC):  
   Days supplied: 150 (5 months) 
   Follow-up time*: 150 days (5 months) 
   PDC = (150)/(150) = 1.0 
 
Figure 15. Example 4: Overlapping fills of 2 different therapies 
PDC adjustments will also be made for those who are hospitalized. We will assume that a 
patient is receiving their medications through the facility during hospitalization and if a patient 
accumulates an extra supply of their medication during the hospital stay, that supply can be used 
once he/she returns home.119  If there is a gap between hospitalization discharge and prescription 
fill, we will shift days’ supply that overlap with the stay to uncovered days after the end of the 
relevant stay, if applicable.119 Hospitalization may also be due to adverse effects of treatment, 
resulting in patients not receive mRCC treatment during hospitalization. Figure 16 provides 
illustrations of the implementation of these scenarios when calculating PDC. In this example, 
there is a 15 -day hospitalization in month 3. Assuming patients are receiving treatment during 
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hospitalization, we will add the 15 days of treatment during hospitalization to the 330 days’ 
supply. 
Month 1 2 3 4 5 6 7 8 9 10 11 12 
First-line therapy 
(30-day supply)                         
Hospitalization (15-
day)                            
Treatment during hospitalization 
Proportion of days covered (PDC):  
   Days supplied: 330 days 
Hospital stay: 15 days 
   Follow-up time: 365 days 
   PDC = (345)/(365) = 0.95 
 No Treatment during hospitalization 
 Proportion of days covered (PDC):  
   Days supplied: 330 days 
   Hospital stay: 15 days 
   Follow-up time: 365 days 
   PDC = (330)/(365) = 0.90 
 
Figure 16. Example 5: 1-year adherence with a 15-day hospitalization. 
To explore the impact of mortality on adherence measures, we will use 2 definitions of 
PDC to calculate adherence. The first definition uses a “fixed” PDC where the number of days 
covered by therapy is divided by a specified period of time (e.g. 6- or 12-months). This is 
considered a “fixed” PDC because the denominator is set to the time of interest to the 
investigator regardless of time on treatment.  
 
 
The second definition is a “variable” PDC where the number of days covered therapy is 
divided by the time between the dates of the first fill to the last day of the days’ supply of the 




Adherence will be calculated for both PDC using a threshold PDC ≥ 80% to define 
adherent vs. non-adherent. While no optimal cut point for high vs. low adherence has been 
defined for TT use, 80% PDC was chosen for this analysis as it is widely used in research 
evaluating medication adherence and has been shown to be a reasonable cut point for stratifying 
patients with low and high adherence.120  
D.3. Covariates  
We will evaluate the following characteristics associated with adherence and persistence: 
age at diagnosis, sex (male or female), SEER regions (Northeast, Southeast, West, and North 
Central), socioeconomic status as measured by having a low income subsidy or living below the 
poverty line, urban vs. rural, year of diagnosis, Frailty Index Score, and the Gagne combined 
comorbidity index.121 The following clinical characteristics available in SEER will also be 
evaluated: histology group (clear cell, non-clear cell), site of metastasis (lung, brain, liver, other), 
nodal involvement (N0, N1, unknown), and tumor size (T1a, T1b, T2, or unknown). Indicators 
of frailty will be measured using a validated Medicare claims-based algorithm developed by 
Faurot et al using ICD-9 diagnosis and procedure codes and CPT and HCPCS codes.122 These 
predictors included demographic characteristics, durable medical equipment charges, and 
geriatric syndromes (Appendix 7).122 Using this algorithm, we will obtain the predicted 
probability of frailty and categorize the continuous variable into the following categories: low (0 
%-< 10%), low/intermediate (10 %-< 20%), intermediate/high (20 %-< 50%), high (≥50%). The 
is a single numeric comorbidity score for predicting short-and long-term mortality, by combining 
conditions in the Charlson and Elixhauser measures (Appendix 4).121 We will assess the numeric 
risk score as a predictor of utilization. We will categorize the continuous score variable as 0, 1, 
and 2 or more.  
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D.4. Statistical analyses.  
D.4.1. Adherence.  
We will then describe the proportion of patients who are adherent (PDC ≥80%) over the 
3-, 6-, and 12-month observation periods using three approaches. Adherence to TT calculated 
with the fixed PDC will be assessed at 3, 6, and 12 months from the index date. To compare the 
impact of mortality on adherence measures patients who die within 3, 6, and 12 months of the 
index date will be first included for each analysis. PDC after death will be assigned zero until the 
end of the fixed time period. We will then run the analysis for each time-period excluding those 
who died. Adherence calculated by the variable PDC will not exclude patients who die. 
However, because this approach only measures the time on treatment, any time after a patient’s 
death will not be included in the denominator. The median PDC and interquartile range (IQR) 
will be reported in days for each measure.  
D.4.2. Non-persistence.  
We will describe the median and interquartile range of time (in days) to time to first-line 
treatment discontinuation. We compare two approaches for handling death as a competing risk 
for non-persistence. We first fitted a Cox proportional hazard model123 to obtain the baseline 
Kaplan Meier estimates, censoring patients at death. This approach accounts for death by 
assuming that the competing risk can be prevented.124 We will then obtain the cumulative 
incidence function of non-persistence generated using Aalen-Johansen risk functions.125 Instead 
of censoring, death is indicated as a competing risk. It assumes in closed cohorts with no loss to 
follow-up, it corresponds to an observable quantity: the number of cases divided by the 
population size at baseline. Even though the Kaplan Meier approach is most commonly used to 
describe non-persistence, discontinuation events for these patients are essentially imputed based 
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on the experience of those who remain under observation. Thus, misinterpretation o f the Kaplan-
Meier estimator as a 1-CIF estimator can lead to upward bias in risk estimates because 
conditional risk will always over-estimate CIF risk functions. These functions will be plotted to 
illustrate the impact of mortality on the risk of non-persistence.  
D.4.3. Subgroup and sensitivity analyses.  
  Subgroup analyses will be conducted across each database. In a sensitivity analyses, we 
will vary the grace period (15, 45, 60 days) to evaluate the robustness of our results to this 
assumption. We will also restrict the analyses to patients who had at least two prescription fills 
and re-categorizing discontinuations as deaths that occurred within the 30-day grace period, and 




CHAPTER 4: VALIDATION OF ALGORITHMS TO IDENTIFY INCIDENT 
METASTATIC RENAL CELL CARCINOMA AMONG MEDICARE BENEFICIARIES 
 
Background:  
Renal-cell carcinoma (RCC) constitutes up to 85% of all kidney neoplasms with 
approximately 33% of patients diagnosed with RCC presenting with regional or distant 
metastasis.4,7 The rapid influx of new metastatic RCC (mRCC) treatment options has 
dramatically changed the treatment landscape, posing unique challenges in clinical practice as 
patients who initiate first-line therapies often receive subsequent lines of therapy due to 
treatment failure, drug resistance, or toxicity5. Thus, comprehensive studies are needed to 
understand the delivery of care to patients in real-world settings.  
Healthcare claims data may represent a potentially powerful resource to (1) elucidate 
potential risk factors associated with incident mRCC and (2) understand mRCC treatment 
utilization, safety, and effectiveness. These data capture detailed, longitudinal information on 
diagnoses, procedures, medications, and healthcare visits for well-defined patient populations in 
clinical practice settings. Most commonly used approaches to identify mRCC patients in claims 
data require the presence of at least 2 claims with a primary diagnosis for RCC and at least 1 or 2 
claims with a diagnosis of metastatic disease.41,77,79,82,88,89  Studies specifically interested in 
patients who received mRCC treatment may also require at least one pharmacy claim for the 
treatment/s of interest. Yet, because these data lack clinical detail, reliance on diagnosis codes
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for RCC and metastasis alone may lead to misclassification of mRCC and hinder study 
validity.126 In fact, previous studies assessing the validity of claims-based algorithms using 
diagnosis codes to identify metastatic disease in breast, colorectal, and lung cancers have 
reported substantial misclassification.85,87 However, to date, no validation study has been 
conducted to evaluate the performance of claims-based algorithms to identify incident mRCC 
patients.   
Thus, the objectives of this study were to develop and validate various algorithms to 
identify patients with incident mRCC using Medicare claims. Here, we evaluated several 
combinations of diagnosis codes, prescription fills, and/or specific procedures related to mRCC 
diagnosis and treatment to improve algorithm accuracy and explore potential use cases.  
METHODS:  
Data source   
We used the SEER-Medicare linkage representing >3.3 million individuals in SEER 
along with their Medicare enrollment and claims data. The National Cancer Institute’s SEER 
program is a surveillance system collecting demographics, clinical and tumor data, selected 
treatments, vital status, and cause of death for all individuals diagnosed with cancer within one 
of 18 SEER regions, currently covering 34.6% of the cancer population in US.115 Medicare 
claims provide information on service dates, diagnoses, procedures, and prescription dispensing 
(since 2007) for covered individuals.115  
Study population  
Older adults with a diagnosis of RCC were identified using the ICDO-3 site code: C64.9 
and histology codes indicative of RCC (8120-8131, 9050-9055, 9140, 9590-9992) from 2007-
2015. Metastatic disease was classified as (1) stage IV or M1 according to then AJCC TNM 6th 
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Edition staging system or (2) distant according to the SEER summary stage. Because only the 
month and year of diagnosis are available in SEER, the date of diagnosis (or the index date) was 
assigned to the first day of the diagnosis month.115,117 We also used a 5% random sample of 
individuals from the SEER regions to identify individuals without mRCC. Importantly this 
sample includes individuals without any cancer history, as well as those with a history of cancers 
other than mRCC (including earlier stage RCC).  RCC patients missing stage were excluded 
from the analysis. 
Calendar-time 
To appropriately account for calendar-time for those ultimately diagnosed with mRCC 
during the study period, we used a moving windows approach to analysis. We determined that 
10-month enrollment windows would be sufficient to identify (1) procedures related to 
diagnostic work-up, symptoms, and confirmatory diagnosis (6 months) and (2) the initial course 
of treatment or death (4 months). As such, for all individuals (both those diagnosed with mRCC 
and those without), we constructed a series of 10-month continuous enrollment windows 
(requiring Medicare Parts A, B, and D coverage), advancing each window by 1-month 
increments from the start of enrollment until disenrollment or death. Figure 5 and Figure 8 
illustrates this moving window design for two hypothetical individuals – one who is never 
diagnosed with mRCC during the study period (Figure 5) and the other one who is diagnosed 
with mRCC on month 17 (Figure 8). Further details about defining case status for each window 
are described in the following section.  
Outcome assessment 
mRCC status was determined for all windows for each individual. Windows were either 
assigned as an mRCC case or non-case window.  mRCC status in SEER data was used as the 
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reference standard to compare our claims-based mRCC definitions. The reference standard case 
window was defined as the window belonging to each mRCC patient that contained 6 months of 
continuous enrollment prior to the date of diagnosis through 4 months following diagnosis or 
death (whichever occurred first). As such, the reference standard case window always occurs on 
the 1st day of the 7th month (Figure 10).  This referent case window is also illustrated in Figure 8 
between months 11 and 19. To address potential candidate predictors in similar windows, we 
assigned the first day of the seventh month as the index date for all case and non-case windows 
(Figure 6).  
All windows occurring prior to the diagnosis date were assigned non-case status in the 
analysis. However, a flag was created for windows that included up to 6 months prior to the date 
of diagnosis (i.e. index date), but did not include the date of diagnosis itself. Patients have not yet 
been diagnosed with mRCC and are technically non-cases; however, these windows include 
periods of time with some symptoms or diagnostic work-up related to their mRCC diagnosis. 
Therefore, these windows are less similar to true non-case windows and more reflective of being 
almost cases. In Figure 8, almost case windows begin on months 2-7 and overlap with the 6-
month diagnostic work-up period. In a sensitivity analysis, these windows were excluded.  
All other windows occurring prior to almost case windows were classified as non-case 
windows (Figure 8). All windows belonging to individuals who were not diagnosed with 
incident mRCC were defined as non-case windows. Windows belonging to mRCC patients who 
did not fulfill the 4 months of continuous enrollment after diagnosis criteria despite being alive 
were excluded. These windows were deemed as not having enough information following the 
index date to define case status. In Figure 8, these windows begin in months 8-10. It is important 
to note that these windows were not excluded if a patient died within 4 months of diagnosis. For 
 
57 
more detailed description of case status assignments for patients who died within 4 months of 
diagnosis (Figure 9).  All enrollment windows occurring after an mRCC case window is 
identified were considered prevalent case windows and also excluded. These were represented in 
windows beginning in Month 12 and on in Figure 8.  
Algorithms 
Several algorithms were constructed to identify observation windows where individuals 
were met definition for incident mRCC. The first set of algorithms (Algorithms 1a and 1b) were 
constructed based on ICD-9 diagnosis codes alone, requiring at least two primary or secondary 
ICD-9 diagnosis codes for RCC (189.0) and at least one primary or secondary diagnosis code for 
metastasis (196.XX-198.XX):  
• Algorithm 1a:  Similar to the most commonly used definition developed by 
Setoguchi et al, we defined mRCC cases in windows where individuals had 
diagnosis codes for RCC and metastatic disease on any inpatient or outpatient claim 
within 60 days.86  
• Algorithm 1b: To more accurately identify the timing of an mRCC diagnosis, we 
defined mRCC cases in enrollment windows where individuals had diagnosis codes 
for RCC and metastatic disease on any inpatient or outpatient claims specifically in 
months 6-8 (i.e., months corresponding to the months before and after the index 
date, see Figure 11).  
For the second set of algorithms (Algorithms 2a-2d), using the 2019 National 
Comprehensive Cancer Network (NCCN) guidelines11 and clinical input, we identified 
diagnostic and procedure codes suggestive of symptoms and diagnostic work-up within the first 
7 months of the enrollment window and treatment or death were identified within say in the 
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index month and the following 3 months (i.e., months 7-10). Diagnostic work up included needle 
biopsy and advanced imaging indicative of metastatic disease (brain MRI, bone scan, spine CT 
or MRI, and PET scan). Symptoms were categorized as mRCC symptoms (hematuria, abdominal 
pain, bone pain) and general symptoms (anemia, weight loss, fatigue, fever). Treatments for 
mRCC included nephrectomy, sunitinib, sorafenib, pazopanib, temsirolimus, everolimus, and 
bevacizumab + interferon-alpha. Each of the following algorithms constructed required at least 
two primary or secondary ICD-9 diagnosis codes for RCC and at least one primary or secondary 
diagnosis code for metastasis in months 6-8: 
• Algorithm 2a (diagnosis codes + diagnostic workup + symptoms): We defined 
mRCC cases in enrollment windows having diagnosis codes for RCC and metastatic 
disease plus at least 1 procedure code related to diagnostic work-up and at least one 
symptom related to mRCC disease.  
• Algorithm 2b (diagnosis codes + diagnostic workup/symptoms + treatment) :  We 
defined mRCC cases in enrollment windows having diagnosis codes for RCC  and 
metastatic disease plus at least one procedure code related to diagnostic work-up and 
1 drug code for mRCC treatment.  
• Algorithm 2c (diagnosis codes + diagnostic workup/symptoms + treatment/death): 
Having diagnosis codes for RCC unspecified disorder of kidney and ureter and 
metastatic disease within in months 6-8 plus at least 1 procedure code related to 
diagnostic work-up within 6 months prior to the index date and 1 drug code for 
mRCC treatment or death within 4 months after. 
• Algorithm 2d (diagnosis codes for RCC and renal mass + either a code for metasta tic 
disease or codes related to diagnostic workup/symptoms + treatment/death): Finally, 
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to maximize sensitivity, additional algorithms were created to define mRCC cases in 
enrollment windows that included at least two primary or secondary ICD-9 diagnosis 
codes for RCC or unspecified disorder of kidney and ureter (ICD9-XX) and at least 
one primary or secondary diagnosis code for metastasis in months 6-8 or evidence of 
diagnostic workup, symptoms, and treatment or death related to mRCC.  
All diagnostic and procedure codes indicating symptoms, diagnostic work-up or treatment of 
metastatic RCC were defined using Current Procedural Terminology (CPT) codes, Healthcare 
Common Procedure Coding System (HCPCS), ICD-9 diagnosis and procedure codes, and 
National Drug Codes (NDC) listed in claims (see Appendix 4).  
Statistical Analysis 
Characteristics of mRCC case and non-case windows were described, including age, sex, 
race, and SEER region. Windows belonging to the 5% non-mRCC sample were up weighted to 
represent the full eligible Medicare population within the SEER regions. Generalized estimating 
equations were used to calculate the sensitivity (SE), specificity (SP), and positive and negative 
predictive values (PPV and NPV, respectively) for each algorithm with 95% confidence intervals 
(CI) at the window level. Sensitivity analyses were conducted to include excluded case windows.   
RESULTS  
We identified 2,506 individuals diagnosed with incident mRCC and 352,033 individuals 
who were not diagnosed with mRCC who were continuously enrolled in Medicare Part A, B, and 
D programs. There were 2,506 referent mRCC case windows and 18,386,707 non-case windows. 
Of non-case windows, 80,885 windows belonged to mRCC cases (0.4%). The median number of 
windows belonging to mRCC cases was 24 (interquartile range (IQR): 11, 43) vs. 33 windows 
(IQR: 14, 58) in non-cases. Table 6 shows the demographic and clinical characteristics of the 
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study population by case status at the window level. The median age ranged from 75-76 years. 
For both case and non-case windows, the majority was white (80%). There were more males 
(56%) in the mRCC group than in non-case windows (37%). Of the 2,506 incident mRCC cases, 
45% initiated treatment, 41% died, and 14% did not receive any treatment within 4 months of 
diagnosis. 
The number of cases, sensitivity, and PPV of the different claims-based definitions are 
shown in Table 7. All definitions showed very high specificity (>99%), whereas sensitivity 
varied between 28%-79%, and PPV was generally very low, ranging between 14%-42%. 
Algorithm 1a (diagnosis codes occurring within 60 days) had high sensitivity.  After 
incorporating the timing of diagnosis codes and symptoms from 6 through 8 months within each 
window for Algorithm 1b, the sensitivity decreased from 78.55% (95% CI: 76.94%, 80.19%) to 
68.56% (95% CI: 66.76%, 70.40%); however the PPV markedly increased from 14.28% (95% 
CI: 13.19%, 15.47%) to 25.80% (95% CI: 23.37%, 28.49%). The sensitivity decreased further to 
58.66% in Algorithm 2c, when diagnostic work-up, symptoms, treatment, and death, were added; 
however the PPV markedly improved to 38.3%. In algorithm 2b the sensitivity was significantly 
reduced when treatment alone was included in the algorithm, underscoring the impact of high 
mortality in this population. 
Overall, algorithm 2a which required at least one diagnostic work-up and at least 
one symptom had the highest sensitivity (58.66%, 95% CI: 56.76%. 60.62%) and PPV 
(42.86%, 95% CI: 38.13%, 48.17%).  Algorithms that included at least two primary or 
secondary ICD-9 diagnosis codes for either kidney cancer or renal mass and either at least 
one primary or secondary diagnosis code for metastasis in months 6 -8 or evidence of 
diagnostic workup, symptoms, and treatment or death related to mRCC showed the highest 
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sensitivity of 84.72% (95% CI: 83.32%, 86.14%) with similar PPV to algorithm 1b.  No 
differences in algorithm performance was observed when algorithms were stratified by sex 
or race/ethnicity (white, black, or other). However, compared to older age groups, sensitivity was 
higher in the youngest age groups (ages 66-74), but no differences were observed in PPV across 
algorithms (Tables 8-13).  
DISCUSSION:  
We evaluated the agreement between mRCC cases identified in Medicare claims and SEER 
cancer registry data using several claims-based algorithms. Results from this study showed claims 
data can be used to identify incident mRCC with very high specificity but the rare disease leads to 
low to modest PPVs. The most commonly used approach for identifying mRCC patients in 
published claims-based studies only requires diagnosis codes for RCC and metastasis.41,77,79,82,88,89   
Our results showed this algorithm had high sensitivity, yet had the lowest PPV (25%). Because 
PPV is dependent on the incidence of disease that is very low for mRCC, lower PPV estimates 
were not surprising. However, results from this study showed that incorporating clinical 
knowledge into algorithms can substantially improve the PPV to over 40%.  
 Determination of which algorithm should be used depends on the specific research 
question. Researchers may prioritize high sensitivity algorithms to ensure all patients are identified 
for a study. If, however, researchers are interested in relative effects of a drug on the incidence of 
mRCC, then having high specificity will be preferred ad perfect specificity will lead to unbiased 
RR estimates (even if there is imperfect sensitivity).127. Alternatively, an algorithm with high PPV 
may be prioritized for cohort selection of mRCC patients as it ensures that all identified cases are 
truly positive. Yet, by prioritizing PPV, the algorithm may not capture all persons with mRCC. 
Moreover, algorithms requiring patients to have specific diagnostic procedures, symptoms, and 
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treatment may restrict the generalizability of the patient population.127 Thus, in addition to 
prioritizing measures of validity, researchers should also carefully consider the target mRCC 
population of interest to determine which algorithm is most appropriate for use. For instance, the 
mRCC population has several distinct sub-populations such as patients who receive treatment 
shortly after diagnosis, patients who die soon after diagnosis, patients who delay treatment due to 
favorable prognosis, and patients who do not receive any treatment at all. By requiring patients 
who died or received treatment after diagnosis, our results showed a lowered sensitivity because 
patients who did not die or receive treatment were excluded, yet this algorithm showed the highest 
PPV. Therefore, to balance higher sensitivity and PPV while capturing a more generalizable 
mRCC population, in which prevalence is low, the algorithm that includes diagnosis codes for 
mRCC, diagnostic workup, and symptoms related to mRCC is recommended over others. 
To date, several studies have been conducted to develop and validate algorithms to identify 
various cancer types. However, this is the first to validate and compare algorithms in patients 
newly diagnosed with metastatic RCC. Moreover, this study utilized a novel approach which 
allows individuals who are diagnosed with mRCC to contribute observation windows when they 
were “cancer free” prior to their diagnosis. Prior to cancer diagnosis, their claims data are more 
representative of true non-cases, and therefore, this approach more appropriately incorporates 
changes in case status over time. Failure to do so may potentially overestimate the incidence or 
prevalence of mRCC.  
There are a few limitations which should be noted. Patients diagnosed with mRCC were 
only available through 2015 in the SEER cancer registry. To avoid inconsistencies in coding of 
kidney cancer during the transition from ICD-9 to ICD-10 coding schemes in October 2015, we 
restricted our mRCC patients to those diagnosed up to September 2015. Thus, an updated study 
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will be needed to validate these algorithms in more contemporary populations where ICD-10 
codes are used. Overall, the PPV for each algorithm was generally low, meaning there were a lot 
of false positives. It is likely that the majority of false positives are patients previously diagnosed 
with stage I-III RCC who eventually progressed to metastatic disease (i.e. patients who were not 
newly diagnosed with incident mRCC). Incorporation of diagnostic work-up, symptoms, and 
treatment markedly improved the PPV; however, individually, in clinical practice these 
additional factors do not necessarily distinguish a patient from stage I-III and stage IV, this is 
especially true for patients with stage III disease. For instance, certain mRCC treatments are 
approved for advanced (unresectable stage III) and metastatic RCC, such as sunitinib, sorafenib, 
and pazopanib. Moreover, procedures such as PET scans and Brain MRIs are ordered when 
metastatic disease is suspected; however, claims data do not contain the results of those 
procedures.  Finally, this algorithm was developed and validated in a population of older adults 
and may not be transportable to other claims databases representing younger or commercially- 
insured populations.   
Conclusion 
We assessed the validity of claims-based algorithms to identify individuals with incident 
mRCC compared to a reference standard using cancer registry data. Our findings showed that 
claims data can be used to identify incident mRCC with very high specificity. However, given a 
relatively low PPV, researchers should consider the appropriateness of using diagnosis code-
based algorithms for mRCC cohort identification and outcome classification. Future validation 
studies in mRCC are needed to explore more complex algorithms that can achieve a higher 
estimated PPV. Moreover, this algorithm should be reassessed in different patient populations, 
data sources, and time periods to ensure transportability and utility beyond the Medicare setting.   
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Table 6. Characteristics for patient windows by case status 
 mRCC Case Windows 
(n = 2,504) 
Non-Case Windows  
( n= 18,396,224) 
 
n % n/median % 
Windows 28 11, 52 32 14,58 
Age 76 71,82 75 70, 82 
Age Group 
    
66-75 1,176 46.93 9,747,695 52.99 
76-85 955 38.11 6,062,457 32.96 
86-95 262 10.45 1,665,196 9.05 
95+ 113 4.51 918,370 4.99 
Race 
    
White 2,056 82.04 14,624,998 79.5 
Black  198 7.9 1,397,515 7.6 
Other 252 10.06 2,373,152 12.9 
Sex 
    
Male 1,450 57.86 6,802,415 36.98 
Female 1,056 42.14 11,593,300 63.02 
Urban 
    
Urban 2,156 86.03 16,245,705.41 88.31 
Rural 348 13.89 2,133,885 11.6 
Unknown 2 0.08 17,160 0.09 
Region 
    
Northeast 433 17.28 3,322,446 18.06 
South 648 25.86 3,986,043 21.67 
North Central 336 13.41 1,980,778 10.77 
West  1,044 41.66 7,585,717 41.24 









Table 7. Performance of claims algorithms compared to referent standard case windows 
 
*Individuals with no incident mRCC diagnosis represent a 5% random sample of non-cases from SEER-regions. Because individuals diagnosed with incident mRCC represent 100% of cases, non-case 
windows were up-weighted by 20 to represent a comparable 100% population.  






(n=367,924,480) Sensitivity 95% CI 
Positive 
predicted 
value 95% CI 
Algorithm 1a  78.55% 76.94% 80.19% 14.37% 13.26% 15.56% 
Yes 1,926 11,560       
No 580 367,912,920       
Algorithm 1b  68.56% 66.76% 70.40% 26.80% 24.25% 29.61% 
Yes 1,718 4,940       
No 788 367,919,540       
Algorithm 2a  58.66% 56.76% 60.62% 44.32% 39.43% 49.81% 
Yes 1,470 1,960       
No 1,036 367,922,520       
Algorithm 2b  27.77% 26.07% 29.58% 42.00% 35.46% 49.76% 
Yes 696 1,100       
No 1810 367923380       
Algorithm 2c  47.61% 45.69% 49.60% 49.83% 43.76% 56.75% 
Yes 1,402 2,460       
No 1,104 367,922,020       
Algorithm 2d  58.66% 56.76% 60.62% 42.28% 37.63% 47.50% 
Yes 2,123 49,800       







Table 8. Sensitivity analysis: Performance of claims algorithms excluding almost case windows excluding almost case windows 
 
*Individuals with no incident mRCC diagnosis represent a 5% random sample of non-cases from SEER-regions. Because individuals diagnosed with incident mRCC represent 100% of cases, non-case 
windows were up-weighted by 20 to represent a comparable 100% population.  






(n=366,256,660) Sensitivity 95% CI 
Positive 
predicted 
value 95% CI 
Algorithm 1a  83.09% 80.43% 85.83% 15.50% 13.93% 17.24% 
Yes 1,926 10,520       
No 580 1,926       
Algorithm 1b  68.56% 66.76% 70.40% 26.84% 24.29% 29.65% 
Yes 1,718 4,864       
No 788 366,251,796       
Algorithm 2a  58.66% 56.76% 60.62% 44.40% 39.49% 49.91% 
Yes 1,470 1,841       
No 1036 366,254,819       
Algorithm 2b  27.77% 26.07% 29.58% 42.03% 35.47% 49.80% 
Yes 696 960       
No 1,810 366,255,700       
Algorithm 2c  47.61% 45.69% 49.60% 49.85% 43.77% 56.78% 
Yes 1,193 1,200       
No 1,313 3662,55,460       
Algorithm 2d  58.66% 56.76% 60.62% 42.35% 37.69% 47.59% 
Yes 1,470 2,001       







Table 9. Sensitivity analysis: Performance of claims algorithms excluding almost case windows for males 
*Individuals with no incident mRCC diagnosis represent a 5% random sample of non-cases from SEER-regions. Because individuals diagnosed with incident mRCC represent 100% of cases, non-case 
windows were up-weighted by 20 to represent a comparable 100% population.  






(n=135,189,177) Sensitivity 95% CI 
Positive 
predicted 
value 95% CI 
Algorithm 1a  79.24% 77.16% 81.38% 14.50% 13.06% 16.10% 
Yes 1,126 6,640       
No 324 135,182,537       
Algorithm 1b  69.10% 66.77% 71.52% 45.05% 27.43% 73.99% 
Yes 1,002 2,826       
No 448 135,186,351       
Algorithm 2a  58.76% 56.28% 61.35% 50.62% 30.84% 83.09% 
Yes 852 1,123       
No 598 135,188,054       
Algorithm 2b  29.52% 27.26% 31.96% 48.15% 32.46% 71.42% 
Yes 428 520       
No 1,002 135,188,657       
Algorithm 2c  57.59% 55.10% 60.19% 40.37% 26.37% 61.79% 
Yes 705 680       
No 745 135,188,497       
Algorithm 2d  58.76% 56.28% 61.35% 69.10% 66.77% 71.52% 
Yes 852 1,243       








Table 10. Sensitivity analysis: Performance of claims algorithms excluding almost case windows for females 
*Individuals with no incident mRCC diagnosis represent a 5% random sample of non-cases from SEER-regions. Because individuals diagnosed with incident mRCC represent 100% of cases, non-case 
windows were up-weighted by 20 to represent a comparable 100% population.  






(n=231,148,368) Sensitivity 95% CI 
Positive 
predicted 
value 95% CI 
Algorithm 1a  77.59% 75.09% 80.18% 14.18% 12.54% 16.05% 
Yes 800 4,840       
No 256 231,143,528       
Algorithm 1b  67.80% 65.04% 70.68% 37.50% 17.96% 78.29% 
Yes 716 1,867       
No 340 231,146,501       
Algorithm 2a  58.52% 55.63% 61.57% 50.00% 43.32% 57.70% 
Yes 618 724       
No 438 231,147,644       
Algorithm 2b  25.38% 22.89% 28.14% 41.78% 36.74% 47.50% 
Yes 268 441       
No 788 231,147,927       
Algorithm 2c  53.69% 50.77% 56.79% 48.56% 33.76% 69.86% 
Yes 488 521       
No 568 231,147,847       
Algorithm 2d  58.52% 55.63% 61.57% 67.80% 65.04% 70.68% 
Yes 618 764       







Table 11. Sensitivity analysis: Performance of claims algorithms excluding almost case windows for White Race  
*Individuals with no incident mRCC diagnosis represent a 5% random sample of non-cases from SEER-regions. Because individuals diagnosed with incident mRCC represent 100% of cases, non-case 
windows were up-weighted by 20 to represent a comparable 100% population.  






(n=291,175,575) Sensitivity 95% CI 
Positive 
predicted 
value 95% CI 
Algorithm 1a  78.83% 77.06% 80.63% 14.36% 13.15% 15.68% 
Yes 470 9,460       
No 1,586 291,166,115       
Algorithm 1b  68.97% 67.00% 71.00% 26.92% 24.12% 30.04% 
Yes 1,418 3,850       
No 638 291,171,725       
Algorithm 2a  58.80% 56.71% 60.97% 44.22% 38.87% 50.30% 
Yes 1,209 1,525       
No 847 291,174,050       
Algorithm 2b  28.11% 26.24% 30.12% 41.91% 34.80% 50.48% 
Yes 578 801       
No 1478 291,174,774       
Algorithm 2c  56.32% 54.22% 58.51% 50.00% 43.32% 57.70% 
Yes 981 981       
No 1,075 291,174,594       
Algorithm 2d  58.80% 56.71% 60.97% 41.78% 36.74% 47.50% 
Yes 1,209 1,685       







Table 12. Sensitivity analysis: Performance of claims algorithms excluding almost case windows for Black Race 
*Individuals with no incident mRCC diagnosis represent a 5% random sample of non-cases from SEER-regions. Because individuals diagnosed with incident mRCC represent 100% of cases, non-case 
windows were up-weighted by 20 to represent a comparable 100% population.  






(n=27,839,986) Sensitivity 95% CI 
Positive 
predicted 
value 95% CI 
Algorithm 1a  74.23% 68.32% 80.64% 13.28% 9.98% 17.67% 
Yes 144 940       
No 54 27,839,046       
Algorithm 1b  64.65% 58.32% 71.66% 24.20% 16.94% 34.56% 
Yes 128 401       
No 70 27,839,585       
Algorithm 2a  55.05% 48.54% 62.43% 40.37% 26.37% 61.79% 
Yes 109 161       
No 89 27,839,825       
Algorithm 2b  18.18% 13.53% 24.43% 37.50% 17.96% 78.29% 
Yes 36 60       
No 162 27,839,926       
Algorithm 2c  48.99% 42.50% 56.47% 50.62% 30.84% 83.09% 
Yes 82 80       
No 116 27,839,906       
Algorithm 2d  55.05% 48.54% 62.43% 40.37% 26.37% 61.79% 
Yes 109 161       







Table 13. Sensitivity analysis: Performance of claims algorithms excluding almost case windows for Other Race  
*Individuals with no incident mRCC diagnosis represent a 5% random sample of non-cases from SEER-regions. Because individuals diagnosed with incident mRCC represent 100% of cases, non-case 
windows were up-weighted by 20 to represent a comparable 100% population. 






(n=47,321,984) Sensitivity 95% CI 
Positive 
predicted 
value 95% CI 
Algorithm 1a  79.67% 74.80% 84.87% 15.36% 11.90% 19.82% 
Yes 196 1,080       
No 56 23,720,72       
Algorithm 1b  68.25% 62.74% 74.25% 28.01% 20.38% 38.51% 
Yes 172 442       
No 80 47,321,542       
Algorithm 2a  60.32% 54.57% 66.67% 48.56% 33.76% 69.86% 
Yes 152 161       
No 100 47,321,823       
Algorithm 2b  32.54% 27.24% 38.87% 45.05% 27.43% 73.99% 
Yes 82 100       
No 170 47,321,884       
Algorithm 2c  58.33% 52.55% 64.75% 48.15% 32.46% 71.42% 
Yes 130 140       
No 122 47,321,844       
Algorithm 2d  60.32% 54.57% 66.67% 48.56% 33.76% 69.86% 
Yes 152 161       
No 100 47,321,823       
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CHAPTER 5. COMPARISON OF APPROACHES FOR MEASURING ADHERENCE 




The development of oral oncologic therapies has dramatically changed the clinical 
landscape in oncology. In the last decade, over 50 oral anticancer agents received Food and Drug 
Administration approval. Currently, they represent approximately 25% to 30% of all anti-
neoplastic agents in development.109,110 Increasing use and development of oral anti-cancer 
agents is predominantly driven by patient preference over intravenous (IV) treatment as they are 
easily administered, non-invasive, and can be received at home, thus requiring fewer clinic visits 
and more flexibility in timing and location of administration.96-99,128,129   
However, the shift in treatment paradigm from IV to oral administration of 
chemotherapeutic agents places the responsibility of drug acquisition and administration from a 
trained medical worker to the patient and their caregivers.100 Moreover, oral oncologic therapies 
often require longer-term use and may have complex instructions for administration. Studies 
have shown that the complexity of many oral anticancer regimens and the difficulty managing 
side effects of these drugs in the home are associated with suboptimal adherence.101 Poor 
adherence to treatment can reduce drug efficacy, increase treatment failure, and result in early 
discontinuation of therapy. This is especially concerning for patients with metastatic disease as 
oral targeted therapy (TT) is more often used, and patients treated in the metastatic setting are 
more likely to be frail and have higher risks of toxicities.103  
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Due to the rapid increase in drug approvals for oral TTs for metastatic disease, non-
adherence to oral therapies is an emerging issue. Moreover, treatment pathways and the advent 
of new combination regimens due to pharmaceutical innovation will only increase regimen 
complexity over time. However, there is no gold standard in how adherence should be measured, 
nor is there guidance for how adherence should be assessed in high mortality populations. 130-132 
Several  methods are used to measure adherence and persistence across cancer types with the two 
most common claims-based approaches to estimating adherence being defined by an 80% 
threshold of proportion of days covered (PDC) or medication possession ratio (MPR).113 
However, most adherence studies for oral neoplastic therapies are conducted in patients with 
non-metastatic diseases. Application of these same measures is challenging in the metastatic 
setting where death is a major competing risk for therapy continuation. To implement many of 
the traditional adherence measures, patients either have to survive a certain time period or those 
who die are considered non-adherent. Therefore, key decisions about how to handle mortality 
must be made when designing and analyzing studies of medication adherence and persistence in 
metastatic cancer populations. To this end, the objective of this study was to compare different 
measures of and approaches to quantifying adherence and persistence to  oral oncologic therapy 
using a motivating example of oral TTs in older adults diagnosed with metastatic renal cell 
carcinoma (mRCC), a particularly high-mortality population.  
METHODS:  
Data source 
We used the Surveillance, Epidemiology and End Results (SEER) program-Medicare 
linked dataset, representing a linkage of >3.3 million individuals in SEER with their Medicare 
enrollment and claims data. The National Cancer Institute’s SEER program is a surveillance 
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system collecting demographics, clinical and tumor data, selected treatments, vital status, and 
cause of death for individuals diagnosed with cancer within one of 18 SEER regions, currently 
covering 34.6% of the cancer population in US.115 Medicare claims provide information on 
service dates, diagnoses, procedures, and prescription dispensing for covered individuals. 115 
Study population 
We identified patients diagnosed with a first primary mRCC aged 66 years or older from 
January 2007-September 2015, who initiated an oral TT within 4 months of diagnosis.  
Individuals diagnosed with RCC were identified using the International Classification of Disease 
for Oncology, Third Edition site code: C64.9 and histology codes indicative of RCC (8260, 
8310, 8316–20, 8510, and 8959). Stage IV RCC cases were identified according to the American 
Joint Committee on Cancer, 6 th Edition staging system. Because the day of diagnosis is not 
available in SEER, we assigned the first day of the diagnosis month as the diagnosis date. To be 
eligible, patients must have continuous enrollment in Medicare Part A, B, and D from 6-months 
prior to and up to 4 months after diagnosis (including the month of diagnosis) or death, 
whichever came first. Prescriptions dispensed for oral TTs available during the study period 
(sunitinib, sorafenib, pazopanib, axitinib, and everolimus) were identified in Medicare Part D 
data using National Drug Codes. The index date was defined as the date of treatment initiation. 
Patients missing stage or reported by autopsy or death certificate were excluded. 
Measures of Adherence and Persistence 
 Adherence to TTs were calculated using the proportion of days covered (PDC) with 
fixed and variable observation periods. A “fixed” PDC was defined as the total number of days 
covered by therapy over a fixed interval period (3, 6, and 12 months).105,118,133 We also computed 
a “variable” PDC which represents a patient’s time on treatment. This was defined as the total 
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number of days covered by therapy over the number of days between the first fill and the last 
refill plus its days of supply.105,118,133 For both fixed and variable PDC’s, we defined adherence at 
a threshold greater than or equal to 80% PDC, as it is widely used in adherence studies and has 
shown to be a reasonable cut point for stratifying patients with low and high adherence.120 
According to the National Comprehensive Cancer Network (NCCN) guidelines, the 
recommended dosing schedule for sunitinib is 4 weeks on and 2 weeks off. To account for this 
cycling, the PDC for periods where patients had 4-week days’ supply and 4 weeks of pills 
dispensed was set to 6 weeks.11 All other NCCN guideline approved dosing schedules for other 
oral TTs had a once or twice daily schedule with no “off weeks” in treatment.  
Persistence to TTs was defined as the time from treatment initiation to discontinuation. 
Patients were persistent to therapies if the duration of one claim (including days’ supplied ) 
overlapped with the date of a subsequent claim. A 30-day grace period was applied between 
successive prescriptions to allow for delays in regular refilling.  Non-persistence was defined as 
discontinuing treatment due to (1) a switch to a different therapy (second-line therapy initiation) 
or (2) lack of a subsequent claim for 1L treatment by the end of the days’ supply plus the grace 
period. The date of discontinuation was assigned to (1) the date of treatment switch, (2) date of 
death, or (3) last day of days’ supply for the last refill for patients who did not die or have a 
treatment switch prior to the last day of days’ supply.  
For overlapping prescription fills for the same drug, the second overlapping prescription 
shifted forward to begin at the end of the days’ supply for the previous prescription. Hospitalized 
patients were assumed to have received their medications through the facility during 
hospitalization. Therefore, if a patient had a drug on hand when hospitalized, their hospital 
length of stay (days) was counted as a fill. If a patient accumulated an extra supply of their 
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medication because of their hospital stay, we assumed that supply could be used once he/she 
returned home.119  If there was a gap between hospitalization discharge and prescription fill, we 
shifted days’ supply that overlapped with the stay to the days following the end of the relevant 
stay.119 
Patient demographics and clinical characteristics 
The following patient demographic and clinical characteristics were summarized at the 
time of mRCC diagnosis: age, sex (male, female), race (white, black, other), marital status 
(married/domestic partner, divorced/widowed/separated, unmarried, unknown), tumor histology 
(non-clear cell, clear-cell), tumor node involvement (N0, N1, unknown), and tumor size (T1a, 
T1b, T2, unknown). In addition, residence in an urban or rural area, Medicare low-income 
subsidy status (full, partial, none), and a census-tract poverty indicator (percentage of residents 
living below poverty) were used to describe socioeconomic status. ICD-9 diagnosis and 
procedure codes, current procedural terminology (CPT) codes, and Healthcare Common 
Procedure Coding System (HCPCS) codes related to frailty and comorbid conditions were 
identified within 6 months prior to the date of diagnosis. The predicted probability of frailty was 
calculated using a validated Medicare claims-based algorithm developed by Faurot et al.122 
These predictors included demographic characteristics, durable medical equipment charges, and 
geriatric syndromes. Gagne comorbidity score121, a single numeric comorbidity score for 
predicting short-and long-term mortality, was categorized as ≤ 0, 1, and 2 or more. 
Statistical Methods 
Adherence and persistence to oral TTs were described at various time points from the 
index date. To evaluate the impact of death on measures of adherence, a variable PDC was 
calculated for all patients, and two fixed PDCs were calculated where (1) patients who died at 
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any point within the specified time period were excluded and (2) patients who died were 
included but assigned zero days covered after death.  A sensitivity analysis was conducted 
restricting the study population to those who had at least two prescription fills.  
To evaluate the impact of death on the measurement of persistence, we obtained the 
baseline hazard functions for the cumulative incidence of non-persistence using two approaches. 
We first fitted a Cox proportional hazard model123 to obtain the baseline Kaplan Meier estimates, 
censoring patients at death. Cumulative incidence functions (CIF) for non-persistence indicating 
death as a competing risk were generated using Aalen-Johansen risk functions.125 These 
functions were then plotted to illustrate the impact of mortality on the risk of non-persistence. 
Sensitivity analyses for non-persistence assessed 15- and 60-day grace periods, re-categorizing 
discontinuations as deaths that occurred within the 30-day grace period, and restriction to 
patients with at least two prescription fills.  
All analyses were conducted using SAS version 9.4 (Cary, NC). This study was approved 
by the University of North Carolina at Chapel Hill Institutional Review Board (18-0632). 
RESULTS:  
After applying inclusion and exclusion criteria, 485 newly diagnosed mRCC patients who 
initiated an oral TT within 4 months of their diagnosis were identified (Figure 17). Of these 
patients, the majority initiated sunitinib (64%) followed by pazopanib (25%). Patients initiating 
sorafenib, axitinib and everolimus comprised of 11% of the population. Overall, 26% had a 
nephrectomy and only 60% had at least two prescription fills. The median age of diagnosis was 
74.2 years (Interquartile range (IQR): 69.8, 78.9) with a predominance of men (59%) and white 
race (80%). Overall, 21% of patients had an intermediate Gagne combined comorbidity score 
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and 8% had a high comorbidity score. Almost a third (27%) of patients died within 3 months of 
treatment initiation, increasing substantially over time. By 4 months 40% of patients died, and by 
12 months 61% died. More detailed demographic and clinical characteristics of the cohort are 
presented in Table 14. 
Adherence 
 Using the method of assigning days covered as zero after a patient dies, the median 
PDC with a fixed denominator of 6 months was 0.47, IQR: 0.23, 0.80. Alternatively, restricting 
the analysis to those who survived 6 months after treatment initiation resulted in a higher median 
PDC of 0.70, IQR: 0.33, 0.93.  When the PDC was calculated with a variable denominator (i.e., 
days between start of therapy days and last day of the days’ supply from their last acquisition) 
the median PDC was 0.98, IQR: 0.74, 1.00 which was higher than both PDCs calculated over a 
fixed time period.  Sensitivity analyses restricted to patients who had at least 2 prescription fills 
showed increased 6-month median PDCs including and excluding patients who died, 0.70  (IQR: 
0.47, 0.93) and 0.82 (IQR: 0.50, 0.97), respectively. No differences were observed in the variable 
PDC after applying the exclusion.  
Figure 18 illustrates how the alternative mortality approaches resulted in different 
estimates of adherence (PDC ≥ 0.80) over time. The proportion of patients identified as adherent 
was higher in the analysis restricting to patients who survived up to 6-months (40%) compared to 
the analysis including these patients and assigning days covered as zero after their death (25%). 
Adherence was consistently higher after restricting to patients who survived across time periods 
with a difference of 13-17 percentage points over time. Yet, overall, estimates of adherence were 
highest at 78% when PDC was calculated using the variable denominator approach. Compared to 
the main analysis, estimates of adherence when calculated using a fixed PDC were higher in the 
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sensitivity analysis restricting to patients who had at least two prescription fills. The 6-month 
adherence estimate when assigning days covered as zero after a patient dies was 40%, and after 
restricting to those who survived, it was 80%. Adherence estimates calculated using a variable 
PDC showed a marginal increase to 81% (Figure 19).  
Non-persistence 
Most mRCC patients either discontinued treatment or died within 12-months of treatment 
initiation (93%). The median time to discontinuation was 77 days (IQR: 42, 162). After 
restricting to those who survived 12-months, the median time to discontinuation was 
substantially higher at 127 days (IQR: 55, 286).  Figure 20 reports the cumulative mortality and 
cumulative risk of non-persistence to oral TTs in mRCC patients over time, showing the two 
methods of handling death. At 12 months, the risk of non-persistence was 0.91 (95% CI: 0.88, 
0.94) when censoring follow-up at death versus 0.75 (95% CI: 0.71, 0.79) when more 
appropriately accounting for death as a competing risk. As expected, sensitivity analyses 
assessing 15- and 60- day gap periods showed non-persistence generally decreased with 
increasing gap periods. After restricting to patients who had at least two prescription fills, the 
CIF for non-persistence was slightly lowered at 0.71 (95% CI: 0.65, 0.76). The CIF for non-
persistence was also lowered to 0.64 (95% CI: 0.60, 0.68) when discontinuations due to deaths 
occurring within the grace period were reclassified as deaths (Table 15). 
DISCUSSION  
This study explored methodologic approaches to account for mortality when estimating 
adherence and non-persistence to oral TTs in incident mRCC patients. By restricting to patients 
who survived, adherence using a fixed PDC (e.g. 6- and 12-months) was substantially higher 
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compared to defining patients as non-adherent (i.e., no covered days) after death. Both 
approaches provide meaningful information regarding medication taking behavior for high short-
term mortality populations; however, these results highlight methodological decisions that must 
be considered and clearly reported.  For instance, researchers interested in understanding 
adherence to inform policies regarding the use and cost of treatment may assign non-adherence 
after death to obtain the proportion of those who achieve adherence within a specific time period. 
With this approach, researchers should expect lowered estimates as non-adherence will be 
predominantly driven by patient deaths. Alternatively, researchers interested in evaluating 
adherence through gaps in prescription fills may only include those who survived within a period 
of time. With this approach estimates can only be generalizable to a unique subpopulation of 
patients with superior prognosis.  
Consistent with other studies84, our results showed adherence to oral TTs decreased over 
time from treatment initiation. Simultaneously, the magnitude of difference from both 
approaches increased at each time point as a result of increasing mortality. To this end, 
calculating adherence using a fixed period may be more useful for medical conditions in which 
patients are expected to survive and remain on long-term therapy. Thus, researchers may instead 
evaluate adherence from the start of treatment until discontinuation for each patient. Compared 
to a fixed period, our results showed higher adherence using a variable PDC. However, with this 
approach, variation in follow-up time due to differences in treatment response, demographics, or 
clinical characteristics within the study population must be considered. Patients with shorter 
follow-up will also have fewer prescription fills, thus providing little time to assess the extent to 
which a patient's actual refilling behavior corresponds to their prescribed regimen.  Moreover, 
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comparison of PDCs using a variable denominator may be difficult to compare across studies 
because of differences between patient populations and follow-up times.   
Given the limitations in measuring adherence when short-term mortality is high, 
obtaining the cumulative risk of non-persistence may be a better measure for understanding 
medication taking behavior in this population. Plots of the CIF for non-persistence may also 
provide better characterization of patterns of persistence in the metastatic setting over time. Yet, 
very often, studies reporting persistence will either (1) exclude patients who died, inducing 
similar concerns related to selection bias, as stated above or (2) account for death as part of the 
definition for discontinuation. Patients who discontinue treatment due to death may have 
substantially different profiles including more severe disease or comorbid conditions than those 
who intentionally discontinue treatment (e.g., treatment failure, experiencing an adverse events 
other than death, patient decision to stop refilling, or treatment switch) and survive. To date, 
studies evaluating time to non-persistence separate deaths from discontinuations often using 
Kaplan-Meier curves, which censors patients at their time of death. This approach accounts for 
death by assuming that the competing risk can be prevented.124  In this study, we propose 
estimating the CIF as it is arguably of much more clinical interest because, in closed cohorts with 
no loss to follow-up, it corresponds to an observable quantity: the number of cases divided by the 
population size at baseline. Further, misinterpretation of the Kaplan-Meier estimator as a 1-CIF 
estimator can lead to upward bias in risk estimates because conditional risk will always over-
estimate CIF. Results from this study illustrates the extent of this bias by showing a lower risk of 
non-persistence with death as a competing risk compared to censoring death. Thus, obtaining the 




However, there are several limitations to this study. Claims-based measures of adherence 
and non-persistence rely on the date of prescription fill and days’ supply. Because there is no 
way to determine whether a patient was truly adherent to their treatment, this study assumed that 
if a medication is dispensed, it has been taken as prescribed. However, studies have shown drug 
exposures obtained through prescription fills and other procedure codes are considered to be 
more reliable than records of physician-ordered prescriptions.134 Reason for treatment 
discontinuation is also not readily available in claims data. Therefore, a discontinuation was 
assumed for those who did not refill their prescription within the 30-day grace period after their 
last day of days’ supply of the last recorded fill. Finally, this study was conducted in older adults 
who likely have a higher baseline risk of mortality compared to younger adults. Therefore, main 
findings of adherence and non-persistence may not be generalizable to newly diagnosed mRCC 
patients less than 66 years of age. However, the recommended methodological considerations 
remain applicable in younger age groups with metastatic disease.   
Despite these limitations, there are several strengths of this study. This is one of very few 
studies to evaluate adherence and persistence in the metastatic setting. The majority of existing 
studies were conducted in cancer populations that either explicitly excluded patients who died or 
excluded those with metastatic disease.74,84,104-110 Studies will also often require patients to meet 
extended continuous enrollment criteria throughout the study period of interest41,82,135, thereby 
implicitly excluding those who died. Importantly, several studies describing methods for 
defining adherence and persistence have been published. Yet, to date, the impact of mortality has 
not been explored. This study demonstrates the effects of higher death rates on the magnitude of 





Few studies of treatment adherence and persistence exist in the metastatic cancer setting. 
With increasing use of oral therapies, adherence and persistence is an emerging issue. Moreover, 
treatment pathways and the advent of new combination regimens will only increase regimen 
complexity over time. Given several challenges in applying traditional medication adherence 
measures in the metastatic setting, future studies should explicitly report the proportion of 
patients who die, the potential for bias, and implications for generalizability of adherence 
depending on which approach is taken. Researchers should also explore more than one approach 
to provide a comprehensive picture of medication taking behavior. Finally, future studies should 
consider obtaining CIFs to account for death as a competing risk and plot functions of non-
persistence to better characterize longitudinal treatment patterns in patients diagnosed with 




Table 14. Baseline demographic and clinical characteristics of patients who initiated an 
oral targeted therapy in the first line (n=485)  
  n/median %/IQR 
1La Therapy type    
Sunitinib 310 63.9% 
Pazopanib 119 24.5% 
Otherb 56 11.6% 
Had a nephrectomyc     
No 360 74.2% 
  Yes 125 25.8% 
Year of diagnosis     
2007-2008 110 22.7% 
2009-2010 81 16.7% 
2011-2012 76 15.7% 
2013-2015 d  97 20% 
Age at diagnosis 74.3 69.8, 78.9 
65-74  263 54.2% 
74-84 196 40.4% 
85+ 26 5.4% 
Sex     
Male 288 59.4% 
Female 197 40.6% 
Race/Ethnicity     
White 387 79.8% 
Black 28 5.8% 
Other 70 14.4% 
Census Tract % < Poverty     
1st quartile (lowest) 100 20.6% 
2nd quartile  127 26.2% 
3rd quartile  139 28.7% 
4th quartile (highest) 119 24.5% 
Low income subsidy     
None 308 63.5% 
Full  158 32.6% 
Partial 19 3.9% 
Urban/Rural     
Urban 422 87.0% 
Rural  63 13.6% 
SEER Region     
Northeast 68 14.0% 
South 129 26.6% 
North Central 69 14.2% 
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West 219 45.2% 
Marital Status     
Married/Domestic partner 289 59.6% 
Divorced/widowed/separated 138 28.5% 
Unmarried 43 8.9% 
Unknown 15 3.1% 
Gagne Combined Comorbidity 
Index     
Low 340 70.1% 
Intermediate 104 21.4 
High  41 8.45 
Faurot frailty prediction  0.041 0.033, 0.057 
Histology Group     
Non-clear cell 73 15.1% 
Clear cell 412 85.0% 
Nodal Involvement     
N0  269 55.5% 
N1  73 15.1% 
Unknown 143 29.5% 
Tumor Size     
   T1a 32 6.6% 
T1b 59 12.2% 
T2 89 18.4% 
Unknown  305 62.9% 
a Abbreviations: 1L = First line 
b Other treatments include sorafenib, axitinib and everolimus 
c Nephrectomy occurred within 4 months of diagnosis 
























Figure 18. Proportion mRCC patients who were adherent (PDC ≥ 80%) to oral targeted therapies 
at 3, 6, and 12-months. This figure depicts the proportion of patients adherent to oral targeted therapies 
over fixed-time periods in two scenarios where (1) patients who died were defined as non-adherent after 
death (black bars) and (2) patients who did not survive through the time period of interest were excluded 






Figure 19. Proportion mRCC patients who were adherent (PDC ≥ 80%) to oral targeted therapies 





Figure 20. Cumulative incidence function for non-persistence with death as a competing risk and 
Kaplan-Meier curve for death and non-persistence where death is censored.  











Table 15: Sensitivity analyses calculating the cumulative incidence for non-persistence treating 





Time to  
non-persistence 3-months 6-months 12-months 
  Median IQR CIF 95% CI CIF 95% CI CIF 95% CI 
Main analysis 71 40, 132 0.46 0.42, 0.50 0.65 0.62, 0.70 0.75 0.71, 0.79 
Sensitivity 
Analyses                 
Grace-period - 
15 days 55 31, 114 0.27 0.23, 0.31 0.42 0.37, 0.45 0.61 0.57, 0.66 
Grace-period - 
60 days 77 42, 162 0.42 0.38, 0.46 0.6 0.56, 0.64 0.71 0.67, 0.76 
Include deaths 
during grace 
period  91 42, 170 0.36 0.32, 0.41 0.54  0.50, 0.58 0.64 0.60, 0.68  
Restriction to at 
least 2 fills 75 113, 198 0.34 0.29, 0.39 0.62 0.57, 0.67 0.79 0.74, 0.84 
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CHAPTER 6: CONCLUSIONS 
A. Summary of findings 
The objective of this research was two-fold. The first aim sought to identify and validate 
an algorithm to identify patients with incident mRCC in health care claims data. The main goal 
of this analysis was to evaluate several algorithms to identify the optimum algorithm for cohort 
selection and outcome definition in patients newly diagnosed with mRCC. The second aim 
sought to evaluate different methods for measuring adherence and persistence in patients with 
mRCC. The goal of this aim was to elucidate the challenges to using traditional measures of 
adherence and persistence in a high mortality population and their implications for bias and 
generalizability.  
For aim 1, using the SEER-Medicare linked data registry (2007-2016), we validated 
several algorithms to identify incident mRCC. Each algorithm was able to detect incident mRCC 
with very high specificity. Traditionally used algorithms (i.e. only including diagnosis codes 
alone) showed the highest sensitivity, yet had the lowest PPV. The algorithm that best balanced 
both higher sensitivity and PPV included codes for mRCC diagnosis and diagnostic work up and 
symptoms related to mRCC diagnosis. However, because prevalence of mRCC is low and 
metastatic cancers are generally challenging to identify using diagnosis codes alone, the positive 
predicted value of most algorithms were low. Thus, researchers must consider the tradeoffs 
between sensitivity, specificity, and positive predicted values for their research question.  
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Aim 2 evaluated the application of traditional approaches to measuring persistence and 
adherence to first line oral targeted therapies in patients diagnosed with mRCC. Adherence was 
first calculated for a fixed period time. When including patients who died, adherence measures 
substantially decreased compared to estimates where patients who died were excluded.  
B. Strengths and Limitations 
Misclassification is a major concern when using claims databases for research. While 
healthcare claims data represent a potentially powerful resource in health research, because 
claims data is collected for billing purposes, the use of diagnosis and procedure codes alone may 
be subject to misclassification. Databases may be subject to coding errors or data omissions. 
Specifically, misclassification of treatment exposure may occur as patients may not have used 
the recorded medication as prescribed after a prescription has been filled. Studies have shown 
drug exposures obtained through prescription fills and other procedure codes are considered to 
be more reliable than records of physician-ordered prescriptions.134 Yet, because measures of 
adherence and persistence rely on the date of prescription fill and days’ supply, there is no way 
to determine whether a patient was truly adherent to their treatment as prescribed.  
There are some limitations to using SEER as the reference standard to develop the 
algorithm.  The SEER program only collects data on the month and year of diagnosis, and does 
not have the exact date of diagnosis. To be consistent with other studies conducted using SEER-
Medicare data, we assigned the diagnosis date at the 1 st day of the diagnosis month. Algorithm 2 
relies upon diagnostic workup, symptoms, treatment, and death related to mRCC. In the clinical 
setting these occur either before and after the diagnosis date. However, because we do not have 
the true diagnosis date, diagnostic work up and symptoms related to mRCC identified six months 
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prior through the one month after the diagnosis date. While some concerns may be raised that the 
diagnosis could have come before the diagnostic work up or symptoms, this should not affect 
cohort selection.   
Risk stratification of patients is important to evaluating medication taking behavior in this 
patient population.11 Prognostic scoring systems are used to categorize patients into risk groups: 
favorable (score = 0), intermediate (score = 1-2), and poor (score = 3+) based on how many 
adverse prognostic factors are present.136,137 Risk scores can influence which treatments are 
received along, which may also impact adherence and persistence to therapies. For instance, 
guidelines recommend pazopanib for specifically for poor-risk patients.11 Prognostic factors used 
to determine a patient’s risk score include Karnofsky Performance Status (KPS), hemoglobin 
value, corrected calcium concentration, absolute neutrophil count, and platelet count, which are 
not all readily available in data sources used in this study. Moreover, patients with different risk 
scores have different prognosis that will impact their survival. Therefore, there may be 
unmeasured confounding due to differences in disease prognosis. Generalizability to broader 
populations is another limitation. This study was conducted in ages 66 and over. These patients 
have more comorbidities, and are generally sicker and frailer. Therefore, these algorithms must 
be validated in younger populations. However, methods and considerations for evaluating 
adherence and persistence can be generalizable to all studies.  
Despite these limitations, there are several strengths to this research. This research is first 
to develop and validate an algorithm to identify patients with incident mRCC in claims data. 
Previous studies of mRCC patient in claims data, have relied upon ICD-9 diagnosis codes alone 
to identify mRCC patients.41,77,79,88,89 Because diagnosis and procedure codes are used for the 
purposes of billing, a diagnosis for incident mRCC may be missed. Misclassification of incident 
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mRCC can also occur when diagnosis codes are used to define the absence of a diagnosis or 
procedure in claims during a specified time period is deemed to be the absence of the condition. 
For instance, prevalent mRCC at the outset of a study may be misclassified as absent and thus 
the first coded observation during follow-up could be misclassified as incident mRCC. Thus, the 
true incidence can be missed due to low algorithm sensitivity (i.e., high false-negative rate), 
resulting in artificially low estimates of mRCC incidence. To improve specificity of incident 
mRCC and study validity, our study will evaluate various methods including machine learning to 
identify the best performing algorithm to identify incident mRCC cases.  
C. Public Health Significance 
Rapid rates of developments in cancer therapeutics over the past decade have 
substantially altered the treatment paradigm for mRCC. These expanded treatment options have 
demonstrated reduced toxicity and been shown to extend survival in clinical trials. Moreover, 
several of these therapies share the same mechanism of action, posing challenges to selecting 
optimal therapy for individual mRCC patients. Physicians may have the greater responsibility in 
this selection process after considering all the patient’s relevant factors including medical 
comorbidities, general performance status, laboratory findings, psychological aspects, and 
financial issues.138 A comprehensive understanding of patterns mRCC treatment, utilization, and 
adherence within the healthcare system is needed to inform not only treating clinicians, but also 
stakeholders at the patient, provider, and insurer levels. It is also vitally important to understand 
which factors may influence their utilization, and identify factors that may provide insight to 
optimizing treatment decisions for mRCC patients. Furthermore, the development of orally 
administered therapies have shifted the responsibility of drug acquisition and administration 
from a highly trained personnel who closely monitored the patient to the patient and their support 
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network. Studies have shown that non-adherence is associated with poorer health outcomes, 
higher hospitalization rates, and progression of disease. Thus, the development of interventions 
to enhance patient adherence and maintain long-term persistence to prescribed therapies is 
critical to ensuring maximum clinical efficacy and to minimize toxicities in mRCC patients. This 
work provides methodological guidance and considerations for researchers using claims data to 
evaluate treatment utilization and medication taking behavior in mRCC patients. Evidence 
generated using these methodologies, will ultimately aid in the development of interventions to 
enhance patient adherence and maintain long-term persistence to prescribed therapies is critical 
to ensuring maximum clinical efficacy and to minimize toxicities in mRCC patients. 
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APPENDIX: DIAGNOSES AND PROCEDURE CODES 
Table A.1: ICD codes: Kidney cancer 
Condition ICD-9 
Malignant neoplasm of kidney, except pelvis 189.0 
Metastatic disease 196.xx - 199.xx 




Table A.2: Morphology codes 
Tumor ICD-O-3 code 
Kidney, NOS C64.9 
Other and unspecified urinary organs C68.0, C68.1, C68.8, C68.9 
 
 
Table A.3: Histology codes 
Tumor Histology ICD-0-3 
Clear Cell Carcinoma 8310, 8311, 8312, 8140, 8005 
Papillary 8050, 8260 
Chromophobe  8270, 8317 
Other History  8000-8004, 8010-8049, 8051-8078, 8141-







Table A.4: Procedure codes for diagnostic work-up 
Procedure CPT/HCPCS codes 
Complete blood count 85004, 85007, 85008, 85009, 85013, 85014, 85018, 85032, 85041, 
85048, 85049 
Urinalysis 81001, 81002, 81003, 81025 
Abdominal/pelvic CT 
with or without contrast 




with or without contrast 
74181, 74183, 72195, 72197 
 
Chest imaging 71260, 71250, 71270, 71275, 71555, 71550 
71552, 71045, 71046, 71047, 71048 
 
Bone Scan 78300, 78305, 78306, 78315, 78320 
Brain MRI  70553, 70553 




36251, 36252, 36253, 36254 
 
 
Nephrectomy 555, 5551, 5552, 5554, 554, 5532, 5534, 5533, 50220, 50225, 
50230, 50234, 50236, 50240, 50545, 50546, 50548, 50543, 50250, 
50542, 50592, 50593, 0135T 50541 
Chemotherapy 96400, 96401, 96402, 96405, 96406, 96408, 96409, 96410, 96411, 
96412, 96413, 96414, 96415, 96416, 96417, 96420, 96422, 96423, 
96425, 96440, 96445, 96542, 96545, 96549, C8953, C8954, C8955, 
G0355-G0363, J8999, Q0083, Q0084, Q0085, S9329, S9330, 
S9331 
Radiation therapy 0082T, 0083T, 4165F, 4181F, 77373, 77401, 77402, 77403, 77404, 
77406, 77407, 77408, 77409, 77411, 77412, 77413, 77414, 77416, 
77418, 77419, 77420, 77422, 77423, 77427, 77431, 77470, 77776, 
77777, 77778, 77789 
Hospice care Q5001, Q5002, Q5003, Q5004, Q5005, Q5006, Q5007,  





Table A.5: Symptoms related to mRCC 
Condition ICD-9 codes 
Adenopathy 785.6 
Disorder of bone and cartilage, unspecified (Bone pain) 733.9 
Hematuria, unspecified 599.7 
Unspecified disorder of kidney and ureter 593.9 
Pulmonary embolism 415.1 
Arteriovenous fistula, 447 
Hemoptysis 786.3 
Pulmonary collapse 518 




Liver  198.7 






Table A.6: ICD codes – Gagne Comorbidity Index 
Condition ICD-9 
Weight: -1  
  HIV/AIDS 042-044 
  Hypertension 401.1, 401.9, 402.10, 402.90, 404.10, 404.90, 
405.11, 405.19, 405.91, 405.99 
  
Weight: 1  
  Hemiplegia 342, 344 
  Alcohol abuse 291.1, 291.2, 291.5, 291.8, 291.9, 303.90-
303.93, 305.00-305.03, V11.3 
  Any tumor 
(except non-melanoma skin- and pancreatic cancer) 
140-156, 158-171, 174-195, 200-208, 273.0, 
273.3, V10 
  Cardiac arrhythmias 426.10, 426.11, 426.13, 426.2-426.4, 426.50-
426.53, 426.6-426.8, 427.0, 427.2, 427.31, 
427.60, 427.9, 785.0, V45.0, V53.3 
  Chronic pulmonary disease 415.0, 416.8, 416.9, 491-494, 496 
  Coagulopathy 286.0-286.9, 287.1, 287.3-287.5 
  Complicated diabetes 250.40-250.73, 250.90-250.93 
  Deficiency anemias 280.1-281.9, 285.9 
  Fluid and electrolyte disorders 276.0-276.9 
  Liver disease 070.32, 070.33, 070.54, 456.0, 456.1, 456.20, 
456.21, 571.0, 571.2, 571.3, 571.40-571.49, 
571.5-571.6, 571.8-571.9, 572.3, 572.8, V42.7 
  Peripheral vascular disorder 440.0-440.9, 441.2, 441.4, 441.7, 441.9, 443.1-
443.9, 447.1, 557.1, 557.9, V43.4 
  Psychosis 295-298, 299.10-299.11 
  Pulmonary circulation disorders 416, 417.9 
  
Weight: 2  
  Congestive heart failure 402.01, 402.11, 402.91, 425, 428, 429.3 
  Dementia 290, 331.0-331.2 
 
100 
  Renal failure 403.11, 403.91, 404.12, 404.92, 585-586, 
V42.0, V45.1, V56.0, V56.8 
  Weight loss 260-263 
  
Weight: 5  




Table A.7. Drug codes 
Drug NDC, GPI, CPT/HCPCS, or procedure codes 


















































































   
high-dose 
interleukin-2 





Table A.8: Indicators of frailty 
Indicator ICD-9, CPT or HCPC code 
Ambulance A0426, A0427, A0428, A0429, A0999 
Home Hospital Bed E0250, E0251, E0255, E0256, E0260, E0261, E0265, E0266, 
E0270, E0290, E0291-297, E0301-304, E0316 
Home Oxygen E1390-1392, E0431, E0433-435, E0439, E0441-443 
Wheelchair E1050, E1060, E1070, E1083-1093, E1100, E1110, E1120, E1140, 
E1150, E1160, E1161, E1170, K0001-9 
Bladder dysfunction 788.3, 788.2, 596.5, 599.6 
Stroke/brain injury 348., 430., 431., 432., 852., 853., 854., 349.82, 433.01, 433.11, 
433.21, 433.31, 433.91, 434.01, 434.11, 434.91 
Coagulopathy 286.6, 286.7, 286.9, 287.4, 287.5 
Skin ulcer 707.0, 707.2, 707. 
Dementia 290., 294., 331., 333.90, 333.92, 333.99, 780.93, 438.0, 797 
Difficulty walking 719.7, 781.2, 781.3, 438.85, V46.3 
Diabetes complication 250.4, 250.6, 250.7, 250.9 
Heart failure 428., 425., 429.0, 429.1, 429.3, 429.4 
Arthritis 719.0, 719.1, 719.4, 719.5, 719.9, 711., 715., 716.5, 716.6, 716.8, 
716.9, 718., 725., 710., 712., 714. 
Lipid abnormality 272. 
Paralysis 342., 438.2, 438.3, 438.4, 438.5, 344., 781.4 
Parkinson’s disease 332 
Podiatric care 700., 703., 681.1 
Psychiatric illness 29., 311., 300.00, 310. 
Rehabilitation care V57.1, V57.21, V57.3, V57.89, V57.9 
Cancer screening V76. 
Sepsis 01., 036. 038., 040.0, 041., 032.0, 032.1, 681.,682., 730., 031.0, 
031.2, 790.7, 032.82, 032.83, 053.0, 053.13, 054.5, 136.3, 320.0, 
785.4, 112.83, 112.81, 112.5 
Vertigo 386., 780.4 
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